European Neuropsychopharmacology (v.20, #S3)

P.3.c.039 Effects of neuroleptic treatment on oxidative stress parameters in schizophrenia patients by A.S. Ivanova; L.P. Smirnova; N.M. Krotenko; A.V. Semke (S480-S481).

P.3.c.038 Quetiapine and norquetiapine efficacy in axiety and depression in major psychosis: a pharmacokinetic approach by M. Mauri; B. Dell'Osso; M. Buoli; S. Paletta; D. Moliterno; S.R. Bareggi; A.C. Altamura (S480).

P.3.c.040 Treatment adherence and tolerability of high doses of risperidone longacting injectable in severe schizophrenic patients by J.j. Fernandez-Miranda; I. Gancedo-Alvarez; M. Redondo-Alvarez; V. Carames-Garcia; A. Sanchez-Garcia (S481).

P.3.c.041 A randomized, double-blind study of paliperidone palmitate and risperidone long-acting therapy in schizophrenia by G. Pandina; R. Lane; S. Gopal; C. Gassmann-Mayer; D. Hough; B. Remmerie; G. Simpson (S481-S482).

P.3.c.042 Antipsychotic polypharmacy and excessive doses are not associated with attentional flexibility in schizophrenia by D. Kontis; S. Kleisas; E. Theochari; S. Kalogerakou; A. Andreopoulou; S. Vassilouli; S. Papakonstantinou; C. Karouzos; E. Tsaltas (S482).

P.3.c.037 A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia by C. Tessier; D. Hoeben; P. Korcsog; D.J.H. Niehaus; K. Aadamsoo; A. Ücok; M. Franco; P. Theodoropoulou; R. Salinas; A. Schreiner (S479).

P.3.c.032 Long-acting risperidone injection versus conventional depots in chronic psychotic patients: a 54 months study by S.L. Romero Guillena; N. Casas Barquero; J.L. Velez Noguera; R. Fernandez-Villamor Ortiz (S476).

P.3.c.031 Risk of metabolic, cardiologic, and endocrinologic abnormalities in patients under long-term antipsychotic treatment by G. Cerveri; A. Mazzocchi; L.S. Volonteri; C. Mannussakis; C. Mencacci (S475-S476).

P.3.c.033 Predictors for treatment response in non-acute patients with schizophrenia by A. Schreiner; C. Tessier; D. Hoeben; M. Lahaye; J. Pfeil; J. Peuskens; F. Rosa; D. Naber; E. Smeraldi; S. Djukic-Dejanovic (S477).

P.3.c.044 Antipsychotic polypharmacy in a community psychiatric clinic by C. Willis; K.S. Naidoo; P. Sawhney (S483-S484).

P.3.c.053 Reasons for switching between antipsychotic drug treatments – the international antipsychotic drug substitution registry by B. Galinska-Skok; P. Paterakis; M. Bubrovszky; P. Thomas; G. Perdriset; L. Pani (S488-S489).

P.3.c.052 Overdose of paliperidone: a case report by J.M. Olivares; C. Cinos; C.P. Losada; F.J. Gutiérrez; M. López (S487-S488).

P.3.c.054 Effect of the DRD2 Taq 1A polymorphism on perospirone and aripiprazole efficacy for Japanese schizophrenia patients by Y. Takekita; M. Kato; M. Wakeno; S. Nonen; S. Tetsuo; S. Sakai; A. Suwa; G. Okugawa; T. Kinoshita (S489).

P.3.c.056 Prolactin elevation induced by antipsychotics in first episode psychotic patients by R. Perez-Iglesias; I. Mata; M.T. Garcia-Unzueta; J.A. Amado; O. Martinez-Garcia; J.L. Vazquez-Barquero; B. Crespo-Facorro (S490).

P.3.c.050 Interaction between polymorphisms of oxidative enzymes and susceptibility to tardive dyskinesia in psychiatric patients by S.A. Ivanova; A.F.Y. Al Hadithy; P. Pechlivanoglou; A.V. Semke; O.Y. Fedorenko; L.A. Levchuk; E.G. Kornetova; J.R.B.J. Brouwers; R. Bruggeman; A.J.M. Loonen (S486-S487).

P.3.c.046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia by M. Schmidt; L. Janssens; J. Kent; I. Anghelescu; G. Hüsken; V. Sinha; E. Mannaert (S484-S485).

P.3.c.048 Treatment with antipsychotics in hospitalised patients with maniac episode by M.C. Garcia Mahia; M. Vidal Millares; M. Gonzalez Santos; C. Armas Barbazan (S485-S486).

P.3.c.030 Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia by T. Sumiyoshi; M. Tsunoda; Y. Higuchi; T. Itoh; T. Seo; H. Itoh; M. Suzuki; M. Kurachi (S475).

P.3.c.011 Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study by H. Detke; P.J. Weiden; T. Lambert; P.M. Llorca; M. Choukour; S.B. Watson; E. Brunner; H. Ascher-Svanum (S464).

P.3.c.008 Correlation between psychotic symptoms and sleep disturbances in schizophrenia by J. Leszczynska; A. Paliga; J. Wieczorek; K. Krysta; I. Krupka-Matuszczyk (S462).

P.3.c.004 Anticholinergic prescribing patterns in patients receiving treatment with antipsychotic medication by F. Oosthuizen; K. du Toit; A.N. Khumalo; N.N.P. Shinga; T. Pillai; K. Pillay; S. Kanhai; T.S. Nhlapo (S460).

P.3.c.006 Olanzapine in the treatment of anorexia nervosa: a case report by A. Capasso; C. Petrella; W. Milano (S461).

P.3.c.007 Compliance of outpatients using long acting antipsychotics with supportive outreaching: a matched case control study by H. Van Loon; H. Vandenbroele; S. De Bruyne; A. Wybo; M. Glorieux; V. Dubois; B. Gillain; J. Peuskens (S461-S462).

P.3.c.016 Cognitive functions and dosage of antipsychotic drugs in Japanese schizophrenia patients by H. Hori; R. Yoshimura; A. Katsuki; K. Hayashi; A. Sugita; W. Nakano; J. Nakamura (S466-S467).

P.3.c.028 Olanzapine in treatment of delusional disorders by N. Zivkovic; D. Pavicevic; G. Djokic; M. Nenadovic; N. Nenadovic; J. Lekovic (S473-S474).

P.3.c.022 Comparison of patients treated with antipsychotics and psychoeducation and those treated with antipsychotics only by C. Istikoglou; D. Foutsitzis; G. Theodorakopoulos; P. Kanellos; N. Polonifis; A. Vlavianou; D. Vlissides; K. Michelidakis (S470).

P.3.c.018 The characteristics of pharmacotherapy for inpatients with schizophrenia: a multicentre comparative study in Asia by W. Nakano; R. Yoshimura; S. Yang; N. Shinfuku; S. Fujii; T. Hoshuyama; K. Sim; M. Chong; C. Tan; J. Nakamura (S467-S468).

P.3.c.019 Community treatment orders and psychotropic medication: baseline data analysis for a one year follow up study (N= 200) by M.X. Patel; J. Matonhodze; M. Baig; J. Gilleen; J. Boydell; F. Holloway; D. Taylor; G. Szmukler; T.J. Lambert; A.S. David (S468-S469).

P.3.c.021 Intramuscular aripiprazole versus injectable haloperidol in treatment of acute psychotic agitation by C. Istikoglou; A. Vlavianou; D. Foutsitzis; G. Theodorakopoulos; C. Polonifis; P. Kanellos; D. Vlissides (S469-S470).

P.3.c.057 Which patients switch antipsychotic medication? Data from the international Antipsychotic Drug Substitution Registry by P. Paterakis; B. Galinska-Skok; L. Pani; M. Bubrovszky; G. Perdriset; P. Thomas (S490-S491).

P.3.c.058 Clozapine-induced agranulocytosis in monozygotic twins and association with multidrug resistance gene MDR1 polymorphisms by A.E. Anil Yagcioglu; B. Cetin Ilhan; M.T. Goktas; M.O. Babaoglu; E. Uz; M.K. Yazici (S491).

P.3.e.009 Clinical analysis of the treatment of schizophrenia (CATS)-study: module assessment of sexual functions by M. Lautenschlager; W. de Millas; A. Lehmann; M. Lambert; K. Leopold; M. Franz; M. Deuschle (S512).

P.3.f.002 Quantifying rater drift in a sample of standardised rater training events: Is PANSS reliability maintained over time? by A. DeFries; C. Yavorsky; M. Opler; L. Ramadhar; E. Ivanova; J. Gordon; S. Jovic; L. Yang (S513-S514).

P.3.e.008 Activation of the immune system with respect to cognitive functioning in schizophrenia by D. Frydecka; A. Beszlej; M. Szewczuk-Boguslawska; M. Zagdanska; L. Karabon; E. Pawlak; A. Kiejna (S511-S512).

P.3.e.007 Sexual activity and marital relationships in Tunisian schizophrenic patients: comparison with healthy controls by Y. El Kissi; M. Laaroussi; S. Gaabout; M. Ayachi; J. Nakhli; B. Ben Hadj Ali (S511).

P.3.e.003 Effectiveness of olanzapine standard oral and orally disintegrating tablets in a 1-year European observational study by F. Chartier; F. Rouillon; M. Lukasiewicz; S. Kraemer; Y. D'yachkova (S508-S509).

P.3.e.005 Total blood cholesterol levels and serum creatine kinase activity in violent psychiatric inpatients by I. Reznik; S. Kertzman; H. Grinspan; M. Birger; N. Shlapnikov; H.Y. Meltzer (S509-S510).

P.3.f.005 Different forms of risperidone and haloperidol in sexual dysfunction among schizophrenic male patients by V. Sibinovic; S. Tosic-Golubovic; D. Gugleta; G. Selimovic; O. Zikic (S515-S516).

P.4.a.001 Quality of life outcomes in obsessive-compulsive disorder: relationship to treatment response and symptom relapse by N.A. Fineberg; D.J. Stein; M. Legault; F. Marteau; E. Hollander (S520-S521).

P.4.a.005 The prevalence of metabolic syndrome in patients with obsessive-compulsive disorder: a cross-sectional analysis by B. Goksan Yavuz; O. Karamustafalioglu; B. Bakim; B. Ozcelik; Y. Cengiz Ceylan; I. Erensoy; O. Tankaya; E. Turkyilmaz; H. Yumrukcal; E. Toprak (S523).

P.3.f.012 Psychoneuroimmune interactions in schizophrenia by O. Lobacheva; T.P. Vetlugina (S519-S520).

P.3.f.007 Atypical antipsychotics and effects of muscarinic and serotonergic receptor binding on insulin secretion in a rat model by M.K. Hahn; A.F. Chintoh; L. Lam; S.W. Mann; A. Giacca; P. Fletcher; G. Remington (S517).

P.3.f.006 Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviours in mice by A. Ortega-Álvaro; A. Aracil-Fernández; M.S. García-Gutiérrez; F. Navarrete; J. Manzanares (S516).

P.3.f.009 A raised glucocorticoid receptor alpha/beta expression ratio in monocytes of schizophrenic and bipolar patients by K. Weigelt; A. Spijker; R.C. Drexhage; J.M. Wijkhuijs; H.A. Drexhage (S518).

P.3.f.010 Continuous perfomance test dysfunction in delusional disorder: an fMRI investigation by F. Akyuz; S. Oflaz; A. Hamamci; Z. Firat; M. Cihangiroglu (S518-S519).

P.3.e.001 Facial emotion recognition deficit in schizophrenia: a replication study in Korean subjects by S.J. Lee; H.D. Rim; Y.W. Park; J.J. Lee; S.M. Jang; J.M. Woo; H.Y. Jo; K.U. Lee (S507-S508).

P.3.d.017 Psychotropic medication use profile and adequacy in elderly institutionalised population by B. Pascual Arce; M.C. Perez Navarro; L. Garcia Sanchez; N. Muro Perea; A. Sicras Mainar; M. Blanca Tamayo (S507).

P.3.c.067 One year study: efficacy of haloperidol versus risperidone in the treatment of schizoaffective disorder by D. Siladji Mladenovic; S. Drezgic Vukic; B. Golubovic; A. Ivezic (S496-S497).

P.3.c.066 Efficacy and safety of long-acting risperidone in schizophrenic stable subjects durring 6 months period by D.G. Gugleta; V.S. Slavkovic; S.T.G. Tosic Golubovic; V.S. Sibinovic; S.D. Stankovic (S496).

P.3.c.065 Comparison of multifactor dimensionality reduction (MDR) and neural network analysis: serotonergic system genes and antipsychotic response by V. De Luca; R.P. Souza; A. Tiwari; H.Y. Meltzer; S.G. Potkin; J. Volavka; J. Lieberman; J.L. Kennedy; A. Serretti (S495-S496).

P.3.c.064 Serum lipide profiles during antipsychotic treatment of schizophrenic subjects by V.S. Slavkovic; S.T.G. Tosic Golubovic; D.G. Gugleta; V.S. Sibinovic (S494-S495).

P.3.c.059 Oxidative stress status in schizophrenic patients treated with typical versus atypical antipsychotics by M. Padurariu; I. Dobrin; C. Stefanescu; A. Ciobica; R.P. Dobrin (S491-S492).

P.3.c.061 Paliperidone palmitate response in acutely ill patients with schizophrenia previously treated with oral risperidone by J.K. Sliwa; C.A. Bossie; Y.W. Ma; A. Schreiner; J.T. Haskins; L. Alphs (S493).

P.3.c.062 The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia by A. Bose; D. Li; R. Migliore; P. Werner; G. Nemeth; I. Laszlovszky (S493-S494).

P.3.c.063 QoL, global functioning and social adaptation of schizophrenic subjects treated with long-acting risperidone by S. Tosic Golubovic; V.S. Sibinovic; V.S. Slavkovic; Z.O. Zikic; D.G. Gugleta (S494).

P.3.d.002 Cognitive impairment in patients with psychotic disorder diagnosis by L. Barbadillo; J. Carton; E. Ibarburu; L. Martin; M. Artola (S498-S499).

P.3.d.013 Energetic metabolism, leptin are altered in rats submitted to chronic administration of olanzapine by A. Zugno; M. Barcelos; D. Fraga; L. Oliveira; L. Canever; R. Luca; G. Rezin; G. Scaini; E. Streck; J. Quevedo (S504-S505).

P.3.d.012 Action of clozapine depends on dopamine receptors presence on target cells -functional study by A. Faron-Gorecka; M. Kusmider; M. Gaska; K. Szafran; J. Solich; P. Palach; M. Dziedzicka-Wasylewska (S504).

P.3.d.014 Continuous paliperidone infusion versus repeated risperidone injections on cognition, prolactinemia and body weight in rats by L. Pani; S. Ruiu; G. Casu; C. Dessì; G. Pinna Spada; A.L. Deriu; G. Marchese (S505).

P.3.d.015 Treatment with memantine and imipramine induces changes in mitochondrial respiratory chain activity in the rat brain by D. Fraga; G. Réus; R. Stringari; G. Rezin; J. Daufenbach; E. Streck; J. Quevedo; A. Zugno (S505-S506).

P.3.d.011 Follow up screening for the metabolic syndrome in patients receiving antipsychotic treatment by L. Konstantinidou; T. Tsouvalas Athanasios; G. Georgiou Georgia; B. Birmpili Euaggelia-Maria (S503).

P.3.d.005 Activity of phosphodiesterase 10A inhibitors in a novel animal model of negative symptoms of schizophrenia by B. Langen; D. Zschaber; H. Stange; T. Hage; N. Brandon; K. Marquis (S500-S501).

P.3.d.009 Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia by X. Langlois; A. Megens; H. Lavreysen; R. Wouters; L. Peeters; P. te Riele; H. Hendrickx; M. Mahieu; M. de Bruyn; G. Macdonald (S502).

P.3.c.002 Association between the alpha-2a-adrenergic receptor 1291 C/G polymorphism and the metabolic syndrome by A. Risselada; J. Vehof; R. Bruggeman; B. Wilffert; D. Cohen; A.F. Al Hadithy; J. Arends; H. Mulder (S458-S459).

P.3.c.001 Association between HTR2C polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study by A. Risselada; J. Vehof; R. Bruggeman; B. Wilffert; D. Cohen; A.F. Al Hadithy; J. Arends; H. Mulder (S458).

P.2.e.024 Cytokine profiles in bipolar affective disorder during acute episodes and in remission by A. Remlinger-Molenda; P. Wojciak; A. Kostrzewa; J. Karczewski; K. Wiktorowicz; J.K. Rybakowski (S415-S416).

P.2.e.026 Parenting and family planning characteristics among bipolar mothers compared to controls by D. Hupfeld Moreno; D. Bio; S. Petresco; D. Petresco; E. Gutt; R.A. Moreno (S416-S417).

P.2.e.027 Association of body mass index with depression and alexithymia by A. Karagöl; G. Ozcurumez; N. Taskintuna (S417).

P.2.f.001 Lithium treatment is not associated with functional or autoimmunitarian thyroideal abnormalities in bipolar disorder I by J. Cobo; E. Patró; J.D. Barbero; M. Pérez; C. Domènech; G. Severino; J.A. Monreal; O. Jiménez-Palop; F. Bleda; G. García-Parés (S418).

P.2.e.022 Lamotrigine adjunctive therapy and possible sleep regulation in adult autism spectrum disorder: a case report by K. Ooga; Y. Abe; T. Okudaira; Y. Suzuki; Y. Ishikawa; Y. Furukawa; T. Kojima (S414-S415).

P.2.e.018 Frequency of mixed states in patients with a major depressive episode:the BRIDGE MIX study by G. Perugi; J. Angst; J.M. Azorin; C.L. Bowden; E. Vieta; A.H. Young (S412).

P.2.e.017 Life-time suicide attempts in acutely admitted inpatients with bipolar disorder by P.I. Finseth; G. Morken; U.F. Malt; O.A. Andreassen; A.E. Vaaler (S411-S412).

P.2.e.019 Thyroid function assessment in lithium-treated patients: preliminary results by A. Lagoudis; I. Iakovou; T. Christoforidis; C. Stergiokoglou; M. Syngelakis; G. Garyfallos; V. Bozikas (S412-S413).

P.2.e.020 Treatment with aripiprazole in Korean patients with acute manic or mixed episodes by Y.H. Ko; I.K. Jung; C.S. Han; J.W. Yang; M.S. Lee (S413).

P.2.e.021 Aripiprazole in combination with lamotrigine: long-term treatment of patients with bipolar I disorder (manic or mixed) by T. Ketter; B.X. Carlson; W. Sun; K. Timko; E. Vester-Blokland; R.D. McQuade; R. Sanchez; R. Owen (S413-S414).

P.2.f.002 Selective DNA methylation of BDNF promoter in bipolar disorder by C. D'Addario; B. Dell'Osso; D. Galimberti; E. Scarpini; B. Arosio; L. Bergamaschini; C. Fenoglio; S. Candeletti; P. Romualdi; A.C. Altamura (S418-S419).

P.2.g.007 Standard antidepressant therapy vs association between amisulpride and antidepressant therapy in atypical depression by G. Grigorescu; A. Baloescu; D. Vasile; C. Tudor; O. Vasiliu; R. Grigorescu (S424-S425).

P.2.g.006 Vagus nerve stimulation in treatment-resistant depression (TRD): results from a systematic neuropsychiatric investigation by E. LaGarde; P. Lespérance; S. Patry; V.S. Tourjman; V. Desbeaumes; A. Bouthillier (S424).

P.2.g.008 Efficacy of milnacipran in patients with interferon-a2 induced depression by M. Zavoianu; A. Cantemir; C. Tudor; G. Grigorescu; D. Vasile (S425).

P.2.g.009 The incidence of psychiatric disorders in patients with hyperthyroidism by R. Chenderes; D.M. Podea; L. Stamoran; P.D. Nanu; C. Mila; L.E. Piros; N. Mihailescu (S425-S426).

P.2.g.010 Taurine levels in plasma before and after three ECT treatments by M. Samuelsson; G. Gerdin; M. Vrethem (S426).

P.2.f.005 Pharmacological treatment in bipolar I and II disorders by N. Varela Gómez; N. Ferrier; J. Mayoral-Van Son; T. Moreno Calle (S420).

P.2.g.002 Sexual dysfunction in depressed subjects with enduring personality change (F62.0) taking mirtazapine by M. Stojakovic; S. Vukadinovic; B. Stojakovic; D. Trkulja; S. Medenica; N. Selman (S421-S422).

P.2.e.016 Psychotic versus non-psychotic bipolar II disorder by A. Murru; L. Mazzarini; F. Colom; I. Pacchiarotti; A.M.A. Nivoli; C.M. Bonnin; G.D. Kotzalidis; E. Vieta (S411).

P.2.d.019 Prefrontal oscillation associated with randomised, placebo-controlled treatment with agomelatine and psychotherapy by B. Loza; M. Polikowska; M. Szubert-Czarnocka; P. Bednarski; J. Grzesiewska; J. Kwasna; A. Mosiolek; I. Patejuk-Mazurek; P. Wnukiewicz; R. Wojcik (S401).

P.2.d.020 Serum VEGF during electroconvulsive therapy (ECT) in drug resistant depressed patients by A. Minelli; R. Zanardini; M. Abate; M. Bortolomasi; M. Gennarelli; L. Bocchio Chiavetto (S401-S402).

P.2.d.015 Adolescent escitalopram administration modifies neurochemical alterations in hippocampus of maternally separated rats by Z.J. Zhang; J.J. Hui; S.S. Liu; G.J. Xi; G.J. Teng; K.C. Chan; G.P. Reynolds (S399).

P.2.d.014 Changes in genes and proteins level of Nr4a1, Egr1 and Id1 in rat brain after antidepressant treatment by M. Gaska; M. Kusmider; J. Solich; A. Faron-Górecka; M. Dziedzica-Wasylewska (S398-S399).

P.2.d.010 Effects of trazodone and paroxetine on expression of hippocampal AMPA receptors and fEPSPs at CA3/CA1 synapses in rats by E. Gerace; G. Stocca; E. Zianni; M. Magnani; L. Polenzani; L. Olivieri; D. Pellegrini-Giampietro; R. Corradetti (S396).

P.2.d.012 Role of 5-HT1A receptor on extracellular 5-HT increase induced by trazodone in the rat prefrontal cortex by B. Garrone; S. De Santi; D. D'Amico; G. Mangano; L. Olivieri; M. Magnani; L. Polenzani; A. Guglielmotti (S397).

P.2.e.012 Use of traditional and alternative therapies in people who suffer bipolar disorders: impact on compliance by S. Strejilevich; M. Scapola; D. Martino; M. Sarmiento; L. Gil; C. Gomez Restrepo (S408-S409).

P.2.e.009 Gender differences in bipolar disorders by A.M.A. Nivoli; F. Colom; A. Rosa R; D. Popovic; I. Pacchiarotti; A. Murru; E. Vieta (S406-S407).

P.2.e.008 Initial antidepressant monotherapy in bipolar depression is associated with more depressive relapses and switches by M. Valentí; I. Pacchiarotti; A.M.A. Nivoli; A. Murru; F. Colom; E. Vieta (S406).

P.2.e.004 Neuropsychological and psychosocial impairment in euthymic bipolar patients by E. Mora; I. Forcada; M. Mur; M.J. Portella; N. Vidal; J. Pifarre; E. Vieta (S404).

P.2.e.005 Mood stabilisers and atypical antipsychotics in the long-term treatment of bipolar disorder by A.C. Altamura; M. Buoli; R.A. Paoli; D. Primavera (S404-S405).

P.2.e.007 Outcome of bipolar illness and comorbid personality disorder by O. Garcia López; P. Fernandez-Argüelles; N. Casas; M. Camacho; J.M. Garcia (S405-S406).

P.2.g.011 Implications of oxidative stress in patients with depressive disorder and insomnia by R. Vitalaru; M. Padurariu; A. Cantemir; A. Ciobica; C. Stefanescu (S426-S427).

P.2.h.001 Polymorphisms in the BDNF gene are associated with antidepressant treatment response by J. Hennings; M. Kohli; A. Heck; D. Roeske; T. Brückl; T. Klengel; A. Menke; B. Müller-Myhsok; M. Ising; F. Holsboer; S. Lucae (S427-S428).

P.3.a.032 Sexual dysfunction in a Tunisian sample of drug free schizophrenic patients: a case-control-study by Y. El Kissi; S. Gaabout; M. Laaroussi; M. Ayachi; J. Nakhli; B. Ben Hadj Ali (S447).

P.3.a.030 Deformities caused by stable body posture in two cases with chronic psychotic disorder by M. Hacioglu; E. Ugurlu; E. Yildirim; S. Erek; O. Saatcioglu (S446).

P.3.a.025 Metabolic syndrome in inpatients with serious mental illness by P. Ntounas; I. Vlachos; R. Psaras; C. Tsopelas; I. Sovolakis; E. Gkeka; M. Dimitraka; E. Siouti; C. Touloumis (S443).

P.3.a.027 Prediction of un-planned readmission to hospital for patients with schizophrenia – a cohort-study of 277 patients by R. Kroken; L.S. Mellesdal; H.A. Jørgensen; T. Wentzel-Larsen; E. Johnsen (S444-S445).

P.3.a.037 Hyperactivation of inflammatory response in depressed patients with psychomotor retardation by G. Camardese; B. Leone; B. Mattioli; G. Pizi; P. Bria (S449-S450).

P.3.a.038 Cannabis-induced psychosis: new entity? by Z. Makkos; L. Fejes; G. Inczedy-Farkas; A. Kassai-Farkas; J. Lazary (S450-S451).

P.3.b.006 Evidence of reduced tiiodothyronine in refractory schizophrenics under clozapine: cause or effect? by P. Belmonte-de-Abreu; C.S. Gama; M.I. Lobato; H. Brentani; R. Massuda; J.A. Palha (S455).

P.3.b.008 Postsynaptic density-95/93 in rat hippocampus affected by NR1/NR2 antisense oligodeoxynucleotide by M. Vrajova; V. Bubeníková-Valeová; M. Fujáková; J. Klaschka (S456).

P.3.b.010 Examination of nociceptive behaviour and stress reactivity in susceptibility gene mutant models of schizophrenia by C. O'Tuathaigh; J. Walsh; O. Tighe; M. Karayiorgou; J. Gogos; R. Harvey; D. Lai; J.L. Waddington (S457-S458).

P.3.b.005 Proton magnetic resonance spectroscopy measures predict a short-time symptomatic outcome in chronic schizophrenia by A. Szulc; B. Galinska; E. Tarasow; B. Kubas; B. Konarzewska; R. Poplawska; N. Waszkiewicz (S454-S455).

P.3.b.004 Advanced paternal age generates higher risk for schizophrenia than for alcohol addiction by B.I. Dragomir; C.N. Marginean; M. Valcu; L. Fodoreanu (S454).

P.3.a.039 Prescribing behaviour of psychiatrists: data from the clinical analysis of the treatment of schizophrenia (CATS) project by N. Bergemann; P. Parzer; F. Rommel; M. Franz; M. Lautenschlager; J. Kammerer-Ciernioch; G. Schindler; P. Wallenfels; M. Weisbrod; M. Deuschle (S451).

P.3.b.001 Seasonality of serum melatonin concentrations in paranoid schizophrenic inpatients by E. Díaz Mesa; A. Morer Fumero; P. Abreu-González; A. Jiménez-Sosa; M. Henry; L. Fernández-López; A. Intxausti; R. Gracia-Marco (S452).

P.3.b.002 Peculiarities of psychotic migrant Romanian patients by A.M. Vremaroiu; L. Fodoreanu; I. Miclutia; C. Popescu (S453).

P.3.b.003 Mapping brain regions in which deep brain stimulation affects schizophrenia-like behaviour in rats – a pilot study by J. Klein; C. Eberhardt; A. Männer; J. Baldassarri; R. Morgenstern; C. Winter (S453).

P.3.a.024 Risk for coronary heart disease in inpatients with serious mental illness by P. Ntounas; C. Tsopelas; I. Vlachos; I. Sovolakis; E. Gkeka; R. Psaras; E. Siouti; C. Touloumis (S442-S443).

P.3.a.005 The impact of cannabis use on cognitive functioning in schizophrenia: a meta-analysis of existing findings and new data by M. Yücel; E. Bora; D.I. Lubman; N. Solowij; W.J. Brewer; S. Cotton; P. Conus; A. Fornito; P.D. McGorry; C. Pantelis (S432).

P.3.a.004 Clinical variables, cognitive assessment and positron emission tomography (PET) in schizophrenic inpatients by M. Buoli; E. Caletti; M. Serati; R.A. Paoli; B. Dell'Osso; A.C. Altamura (S431-S432).

P.3.a.003 Comorbidity of dandy walker complex malformations and schizophrenia, case series by E. Yildizhan; G. Özgen; A. Türkcan; Z. Öztürk (S431).

P.2.h.003 Suicide attempts in a mental health unit of Galicia by B. Pórtela Traba; M. Pérez García; A. Mozos Ansorena (S428-S429).

P.2.h.004 Antidepressant and antipsychotic-like effects of GABA-B receptor ligands in mGlu7 deficient mice by J.M. Wieronska; P. Branski; T. Lech; M. Marciniak; A. Pilc (S429).

P.3.a.001 Evaluation of the effect of aripiprazole on quality of life in patients with schizophrenia by C. Bervoets; E. Constant; B. Sabbe; M. Morrens; K. Vansteelandt; A. De Patoul; D. Pitzi; V. Halkin; J.Y. Loze; J. Peuskens (S429-S430).

P.3.a.002 Evaluation of theta burst stimulation on the resistant auditory hallucinations: a pilot study by D. Sidhoumi; S. Braha; N. Bouaziz; R. Benadhira; D. Januel (S430-S431).

P.3.a.011 Descriptive study of suicidal behaviour in delusional disorder by M. Pérez García; A. Mozos Ansorena; B. Portela Traba; M. Páramo Fernández; J. Brenlla González (S435-S436).

P.3.a.021 Prepulse inhibition in patients with first-episode of schizophrenia: differences related to cannabis abuse disorder by I. Morales; G. Rubio; R. Jurado; M. Caballero; I. Martínez-Gras; G. Ponce; M.A. Jiménez-Arriero; T. Palomo (S441).

P.3.a.017 Global functioning amongst patients at a psychiatric emergency service: preliminary results by N. Manzanares; A. García-Villarrubia; S. Arranz; O. González; A. Sáenz; J. Peña (S439).

P.3.a.012 Alteration in resting state brain connectivity in subjects with high genetic risk of psychosis by J.H. Jang; W.H. Jung; E. Kim; G. Shim; H.Y. Park; D.H. Kang; C.H. Choi; J.S. Kwon (S436).

P.3.a.013 Fatigue, sleepiness and sleep quality in psychotic disorders by C. Widakowich; D. Neu; V. Nagant; G. Steegen; P. Verbanck (S436-S437).

P.3.a.015 Study of the efficacy and safety of risperidone long acting injection in elderly schizophrenia patients by Y. Inoue; H. Suzuki; M. Ootomo; S. Takeda; Y. Kawaguchi; K. Gen (S438).

P.4.a.006 Differences in duration of untreated illness in patients with anxiety disorders by B. Dell'Osso; M. Buoli; L. Lietti; L. Oldani; G. Camuri; B. Benatti; E. Catenacci; C. Bressi; A.C. Altamura (S523-S524).

P.6.f.004 Effect of toluene chronic inhalation on the process of learning in adult and adolescent rats by M. Zhvania; T.Z. Bikashvili; N.J. Japaridze; L. Gelazonia; L. Chilachava; V. Okuneva (S610).

P.6.f.003 Repeated administration of modafinil induces behavioural sensitisation in mice by K. Slais; A. Machalova; D. Vrskova; A. Sulcova (S609).

P.7.a.002 A controlled family study of children with DSM-IV bipolar-I disorder by J. Biederman; J. Wozniak; S. Faraone; E. Mick (S611).

P.6.e.003 Acute psychotic disorder due to the use of ethnobotanical substances by M. Ladea; M. Lepadat; M. Bran; M.C. Sarpe (S606).

P.6.e.005 Suicide and dual diagnosis by R. Martinez; G. Mateu; L. Díaz; L. Morro; R. Rodríguez; D. Martínez; A. Merino; M. Torrens (S607).

P.6.e.006 Cue reactivity in pathological gamblers and smokers: an fMRI study of behavioural and substance related addictions by A.E. Goudriaan; M.B. de Ruiter; J. Oosterlaan; W. van den Brink; D.J. Veltman (S607-S608).

P.7.a.004 Psychiatric outcomes of girls with ADHD grown up: a controlled 11-year follow-up study by J. Biederman; C. Petty; M. Monuteaux; S. Faraone (S612-S613).

P.7.a.005 Antipsychotic metabolic effects in bipolar youth: comparison with other psychotic and non-psychotic diagnoses by M. Rapado-Castro; C. Moreno; J. Merchan-Naranjo; M. Álvarez; I. Baeza; J.A. Alda; C. Martínez-Cantarero; B. Sánchez; E. de la Serna; C. Arango (S613).

P.7.a.012 Dyskinesia in naïve children and adolescents treated with olanzapine, risperidone and quetiapine: three months follow up by J. Merchán-Naranjo; M. García-Amador; M. Leiva-Resino; C. Llorente; C. Tapia-Casellas; M. Giráldez; D. Fraguas; C. Arango (S617).

P.7.a.009 Different levels of salivary steroids in autistic and healthy children by M.D. Majewska; M. Hill; E. Urbanowicz; P. Rok-Bojko; I. Namyslowska; P. Mierzejewski (S615-S616).

P.6.e.001 Cognitive flexibility in pathological gambling and alcohol dependence: an fMRI study by R.J. van Holst; A.E. Goudriaan; D.J. Veltman; W. van den Brink (S605).

P.6.d.028 Dysfunctional response inhibition correlates with reduced gray matter in the inferior frontal gyrus of cocaine abusers by L. Moreno; E.A. Stamatakis; M.J. Fernández-Serrano; E. Delgado-Rico; M. Pérez-García; A. Verdejo-García (S604).

P.6.d.009 Tobacco and suicidal ideation by M. Vidal Millares; M.C. Armas Barbazán; M.C. García Mahía; P. de Usabel Guzmán; L. Vigo Santamariña; M.J. Mota Rodriguez; A. Pampin Alfonso (S593).

P.6.d.008 Association between NrCAM gene variants, working memory and cognition in methamphetamine abuse by B. Lee; Y. Kim; D. Kwon; Y. Chung; J. Park; S. Kim; C. Kang; J. Kim; Y. Lee (S592-S593).

P.6.d.002 Expression of NMDA receptor subunits in human peripheral blood lymphocytes in opioid addiction by R. Roozafzoon; A. Goodarzi; N. Vousooghi; P. Yaghmaei; M. Sedaghati; M.R. Zarrindast (S589).

P.6.d.005 Evaluation of the role of central adenosine A1 and A2a receptors in the development of tolerance to morphine analgesia in rats by M. Charkhpour; A. Parvizpur; F. Ebrahimi; P. Talebi; H. Samadi; Z. Namjo (S590-S591).

P.6.d.024 Serotonergic challenge of memory functions in MDMA users by K. Preller; N. Dörig; F. Hasler; F.X. Vollenweider; B.B. Quednow (S602).

P.6.d.026 Impaired color vision in recreational stimulant users by L. Hulka; M. Wagner; K.U. Kühn; W. Maier; B.B. Quednow (S603).

P.6.d.027 Magnesium as modulator of NMDA receptors in morphine-induced behavioural sensitisation by D. Chelarescu; C. Filip; M. Cuciureanu; O.C. Chelarescu; C. Ghiciuc (S603-S604).

P.6.d.022 The role of serotonin and dopamine systems in the action of the psychedelic 4-bromo-2,5-dimethoxyphenylethylamine (2C-B) by T. Palenicek; M. Fujakova; I. Gorman; L. Rambousek; V. Bubenikova-Valesova; J. Horacek (S600-S601).

P.6.d.021 Cannabinoid CB2 receptor antagonist prevents cannabidiol-induced decrease in body weight gains in rats by B. Ignatowska-Jankowska; M.M. Jankowski; W. Glac; A.H. Swiergiel (S600).

P.6.d.016 Impulsive choice predicts resistance to extinction and vulnerability to reinstatement of cocaine seeking by N. Broos; A.N.M. Schoffelmeer; L. Diergaarde; T. Pattij; T.J. De Vries (S597).

P.6.d.018 Cocaine, morphine and the cannabinoid win55212 depress neuronal activity in the rostromedial tegmental nucleus by S. Lecca; A. Luchicchi; S. Carta; M. Melis; A.L. Muntoni; M. Pistis (S598).

P.6.d.020 Dose-dependent effects of repeated intravenous cocaine on CD4:CD8 lymphocyte ratio in peripheral blood of rats by M.M. Jankowski; B. Ignatowska-Jankowska; W. Glac; A.H. Swiergiel (S599-S600).

Author Index (S649-S668).

Keyword Index (S669-S675).

P.7.c.010 The cost effectiveness of aripiprazole for the treatment of adolescents with schizophrenia by L. Pericleous; E. Dudley; M. Lebmeier; A. Bentley; R. McAllister (S626).

P.7.c.003 One-year follow up of change in functioning in naïve ADHD patients treated with atomoxetine or other standard treatment by R. Escobar; D. Quail; K. De Bruyckere; M. Casillas; P. Berquin; K. Puvanendran; J. Fuentes (S622).

P.7.c.007 Self-injury among Croatian adolescents: important risk factors by K. Dodig-Curkovic; M. Curkovic; D. Degmecic; P. Filakovic (S624).

P.7.e.002 European professionals' attitudes and practices in the management of ADHD by M. Fitzgerald; F. McNicholas; L. Henson (S629-S630).

P.8.a.009 Hospitalisation of immigrant patients in a psychiatric sector of a Greek general hospital by M. Anagnostopoulou; A. Karkanias; A. Tselebis; A. Christodoulaki; A. Karakostas; D. Bratis; G. Moussas (S634).

P.8.a.008 Agressivity management in mobile emergency unit by P. Alvaro; A. Martínez; M. Nascimento; D. Córcoles; A. Malagón; F. Portillo; J. Ginés; M. Bellsolà; L.M. Martín; A. Bulbena (S633-S634).

P.8.a.010 Coercion in psychiatric care: can paternalism justify coercion? by H. Lee; S. Kim; M. Seo; M. Rhee (S634-S635).

P.8.a.012 25-hydroxyvitamin D blood levels in recently admitted psychiatric inpatients by J.J. Mast; K.M. Koorengevel; N.J. van Beveren (S635-S636).

P.8.a.003 Polypharmacy among psychiatric outpatients in Kuwait by S. Eid; N. Alsafar; S. Alqatan; H. Metwalle (S631).

P.4.d.002 Electroencephalographic activity defines the temporal-window for pentylenetetrazole role as an unconditioned stimulus by J. Cavalli; A.A. Hoeller; M. Duzzioni; T.C.M. De-Lima; L.J. Bertoglio; A.P. Carobrez (S545-S546).

P.4.c.006 Day 3&7 jitteriness symptoms predict poor 6 week outcome in SSRI treatment and correlate with day 7 nocturnal activity by D. Christmas; S.J.C. Davies; D.A. Hince; J. Williams; K. Schroeder; D.J. Nutt (S544-S545).

P.4.b.020 Serum BDNF in OCD and major depressive disorder patients before and during antidepressant treatment by L. Bocchio Chiavetto; G. Rosso; R. Zanardini; A. Chiarle; F. Bogetto; M. Gennarelli; G. Maina (S541).

P.4.c.002 Anxiolytic effect of cannabidiol in subjects with social anxiety disorder by M.M. Bergamaschi; M.H.N. Chagas; D.I. Chaves; B.S. Martinis; M.D. Grando; M.C. Freitas; R.H.C. Queiroz; J.E.C. Hallak; A.W. Zuardi; J.A.S. Crippa (S542).

P.4.c.004 Comparison of effect of paroxetine and milnacipran for outpatients with pain disorder by K. Sanada; M. Mimura; Y. Noda; M. Hida; M. Nakahara; A. Tsukurimichi; Y. Kawamura; N. Kato (S543).

P.4.e.005 Obsessionality in the general population and in psychiatric disorders by R.M. Blom; C. de Bruijn; R. de Graaf; M. ten Have; D. Denys (S548-S549).

P.5.a.007 Comparative efficacy of cholinesterase inhibitors in dementia associated with Parkinson's disease by D. Vasile; O. Vasiliu; M.L. Vasile; M. Terpan; G. Grigorescu; V. Bogdan; A. Mangalagiu; M.B. Petrescu; D. Ojog (S553-S554).

P.5.a.009 Relationship between subjective memory complaints and cognitive function in the elderly by K.Y. Lim; K.J. Chang; K.S. Lee; H.J. Kim; H.K. Cheong; B.H. Oh; C.H. Hong (S554-S555).

P.5.a.010 Association between memory age identity and cognition in the elderly by K.Y. Lim; K.J. Chang; H.J. Kim; K.S. Lee; H.K. Cheong; B.H. Oh; C.H. Hong (S555).

P.4.e.006 Aripiprazole augmentation of antidepressant therapy of severe obsessive-compulsive disorder: a preliminary study by M. Casale; R. Braiotta; C. Cerruti; E.P. Di Pierro; T. Guerriero; F. Maucioni; A. Morello; T. Tortorella; A. Mautone (S549).

P.5.a.002 Accessing treatment and services for people with dementia: a pilot study by R. Spencer; S. Curran; N. Roberts; V. Minogue; J. Shewan; J. Wattis (S550-S551).

P.4.b.019 Panic attacks associated with generalised anxiety disorder by M. Van Ameringen; C. Mancini; W. Simpson; B. Patterson (S540).

P.4.b.018 Examining face and construct validity of a non-invasive model of panic disorder in lister-hooded rats by E. Prinssen; L.B. Nicolas; C. Lopez Lopez; L.H. Jacobson; S. Gatti; C. Grundschober; S. Klein (S539-S540).

P.4.a.015 Investigation of predictors of drug response in obsessive compulsive disorder (OCD) by P. Richter; K. Witheridge; Z.J. Daskalakis; J. Deluce; R. Nebitt; N. Rector; A. Levitt; J.L. Kennedy (S529).

P.4.b.014 Effects of diazepam on fear behaviours evoked by a model of panic involving prey versus predator confrontations by A. Francisco; M.A. Castiblanco-Urbina; A. Twardowschy; A. Uribe-Mariño; N.C. Coimbra (S537-S538).

P.4.b.013 Effect of diazepam on conditioned fear evoked by an ethological model of panic involving prey versus predator encounters by M.A. Castiblanco-Urbina; A. Twardowschy; A. Uribe-Mariño; A. Francisco; N.C. Coimbra (S536-S537).

P.4.b.016 Ventromedial prefrontal cortex activity is required for anxiety expression: distinct neurochemical mechanisms evidence by C.A.J. Stern; F.H. Do-Monte; L. Gazarini; A.P. Carobrez; L.J. Bertoglio (S538-S539).

P.4.b.009 Posttraumatic stress disorder and inflammation by G. Mkrtchyan; L. Hovhannisyan; A. Boyajyan; M. Tadevosyan; A. Kalashyan; S. Sukiasian (S534-S535).

P.4.b.00l Neuropeptide S receptor (NPSR) gene – imaging genetic evidence for a role in panic disorder by K. Domschke; P. Ohrmann; A. Pedersen; C. Hohoff; J. Bauer; T. Suslow; H. Kugel; V. Arolt; A. Reif; J. Deckert (S530).

P.5.a.012 Effects of memantine on global clinical status in patients with moderate Alzheimer's disease by S.M. Graham; R.K. Hofbauer; S. Hendrix; M. Tocco; J.L. Perhach (S556-S557).

P.5.a.013 Memantine prevents worsening across multiple domains in a trial of patients with moderate Alzheimer's disease by S.M. Graham; M. Tocco; S. Hendrix; R.K. Hofbauer; M.L. Miller; J.L. Perhach (S557).

P.6.b.002 Can behaviour during computer assisted self-infusion of ethanol (CASE) predict the future risk for addiction? by I. Mick; S. O'Connor; V. Vitvitskiy; P. Winiecki; K.F. Mann; U.S. Zimmermann (S577).

P.6.b.004 Milnacipran reduces alcohol-induced behaviours, alcohol self-administration and relapse in dependent rats by M. Naassila; E. Simon O'Brien; R. Legastelois; H. Houchi; C. Vilpoux; S. Alaux; O. Pierrefiche; E. André (S578-S579).

P.6.b.005 Alterations of nerve growth factor expression and promoter methylation during alcohol withdrawal by T. Hillemacher; M.A. Muschler; H. Frieling; S. Bleich; A. Heberlein (S579).

P.6.a.011 Adequacy of decision making is not associated with long-term abstinence in alcohol addiction by B. Andó; A. Szkaliczki; E. Kurgyis; N. Domján; J. Honti; I. Demeter; P. Szikszay; Z. Janka; P. Almos (S576).

P.6.a.010 Alterations of brain-derived neurotrophic factor serum levels in alcohol dependence patients by R. Zanardini; A. Fontana; M. Gennarelli; L. Bocchio-Chiavetto (S575-S576).

P.6.a.006 Clinical variables related to attentional bias associated with alcohol cues by F. Trujillo; M. Marín; J. Chamorro; P. Curibil; L. Sánchez-Pastor; I. Martínez-Gras; G. Ponce; G. Rubio (S573).

P.6.c.007 A comparison of methadone-maintained patients with and without co-occuring personality disorder by K. Stoychev; K.M. Ivanov; M.G. Alexandrova; R.D. Stoychev (S585).

P.6.c.006 Six month follow-up of cocaine users admitted in an outpatient treatment centre in Barcelona (Spain) by C. Castillo; D. Martinez; R. Martinez; P. Rossi; F. Fonseca; M. Astals; G. Mairal; L.L. Tort; M. Torrens (S584-S585).

P.6.c.008 Respiratory changes following benzodiazepine administration in opioid-dependent human participants by T.M. Williams; R. Lees; R.M. Lovell; G. Henderson; D.J. Nutt; A. Lingford-Hughes (S585-S586).

P.6.c.009 Eplivanserin has no significant abuse potential compared to diazepam and ketamine in recreational drug users by K.A. Schoedel; S. Saubadu; A. Delfolie; J.L. Pinquier; E.M. Sellers (S586-S587).

P.6.c.010 Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users by K.A. Schoedel; N. Chen; G.W. Guy; S. Wright; A. Patel; L. White; C.G. Stott; E. Russo; E.M. Sellers (S587).

P.6.c.005 Attentional bias towards cocaine cues using a dot-probe detection task by G. Rubio; J. Chamorro; S. Moratti; I. Martínez-Gras; P. Campo; G. Ponce (S584).

P.6.c.004 Neurocognitive endophenotypes of stimulant dependence – preliminary findings by S. Pradhan; A.J. Turton; T.W. Robbins; E.T. Bullmore; K.D. Ersche (S583-S584).

P.6.b.009 Alcohol intoxications during adolescence predict later vulnerability to alcohol self-administration in rats by M. Naassila; V. Warnault; M. Kervern; O. Pierrefiche; C. Vilpoux; S. Alaux (S581).

P.6.b.008 Cognitive bias in social alcohol consumers: do stimuli matter? by A. Ataya; S. Adams; M.R. Munafò (S580-S581).

P.6.c.001 Cortisol levels and MDMA-induced memory impairment by K.P.C. Kuypers; J.G. Ramaekers (S581-S582).

P.6.c.002 Impulsivity – an inherited vulnerability marker for stimulant dependence? Preliminary findings by A.J. Turton; S. Pradhan; E.T. Bullmore; T.W. Robbins; K.D. Ersche (S582-S583).

P.6.a.003 Long acting risperidone in heavy-drinkers: a preliminary study of efficacy by M. Marinescu; S. Bisleau; V. Ferri; S. Bulteau; S. Voillet; S. Pradayrol; Y. Bescond; M. Lejoyeux (S571-S572).

P.5.c.001 Memantine improves poststroke cognitive impairment supported with mirtazapine by S. Djukic Dejanovic; D. Djokic; D.R. Milovanovic; M. Borovcanin; D.B. Ravanic (S562).

P.5.c.002 Eating disorders and deep brain stimulation of the subthalamic nucleus in Parkinson's Disease by I. Chéreau; I. De Chazeron; I. Rieu; P.p. Derost; J.j. Lemaire; P.m. Llorca; F. Durif (S562-S563).

P.5.c.003 Psychiatric comorbidity and quality of life in patients candidates to epilepsy surgery by L. Camara Pestana; M. Andreia; A. Carmo; R. Mendes; S. Loureiro (S563).

P.5.b.001 Longitudinal [11C]PIB and [18F]FDDNP PET studies on memory in patients and controls by R. Ossenkoppele; N. Tolboom; W.M. van der Flier; M. Yaqub; A.D. Windhorst; R. Boellaard; F. Barkhof; A.A. Lammertsma; P. Scheltens; B.N.M. van Berckel (S560-S561).

P.5.a.014 Functional communication in patients with moderate Alzheimer's disease treated with memantine by S. Graham; M. Tocco; S. Hendrix; R.K. Hofbauer; J.L. Perhach (S557-S558).

P.5.a.016 Automated classification of MR images for recognising Alzheimer's disease in living patients by F. Simsek; F. Polat; O. Demirel; O. Kitis; D. Haznedaroglu; C. Eker; E. Kumral; A.S. Gonul (S558-S559).

P.5.d.002 The protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on rotenone-induced irregularities in rat brain by L. Antkiewicz-Michaluk; A. Wasik; I. Romanska; J. Boksa; J. Michaluk (S564-S565).

P.5.d.003 Effects of resveratrol on scopolamine and mecamylamine induced memory impairment in rats by N. Gacar; T. Utkan; O. Mutlu; S.S. Göçmez; I. Komsuoglu Celikyurt; G. Ulak (S565).

P.5.e.003 ZOOM: observational genetic screening study of Niemann-Pick disease type C in adults with neurological/psychiatric signs by H. Klünemann; F. Sedel; D. Linden; D. Balding; J.E. Wraith; M.C. Patterson; M. Pineda; J. Priller; C. Remy; P. Bauer (S569).

P.5.e.001 Patient characteristics for misdiagnosed delirium at psychiatric consultation in a university hospital by K.W. Yun; J.W. Choi; H.S. Park; J.H. Ryoo; Y.C. Kim; W.J. Lim; E.J. Kim; S.I. Kim (S567-S568).

P.5.d.005 Midazolam microinjected into inferior colliculus potentiate haloperidol-induced catalepsy by L. Melo; J.G. Tostes; P. Medeiros; N.C. Coimbra; E.A.M. Ferrari (S566).

P.5.d.007 Effects of 5-HT7 receptor ligands in rats suffering from chronic neuropathic pain by F. Viguier; B. Michot; V. Kayser; M. Hamon; S. Bourgoin (S567).

P.2.d.008 Effects of single and chronic agomelatine administration on Galpha(i) proteins expression in the rat brain by P. Chmielarz; K. Wieczerzak; A. Zelek-Molik; J. Kusmierczyk; A. Bielawski; I. Nalepa (S394-S395).

P.2.d.007 The influence of aripiprazole on the antidepressant and memory improving effects in rats by E. Nowakowska; L. Kus; A. Czubak; K. Burda; J. Zin; P. Ratajczak (S394).

P.1.a.015 Association of schizophrenia and dopamine β-hydroxylase (DBH) polymorphism in Korean population by D.S. Moon; J.W. Paik; A.R. Cho; J.W. Kim; E.J. Kim; J.H. Chung (S220-S221).

P.1.a.016 Biochemical and genomical characteristic of mice lacking the noradrenalin transporter by J. Solich; P. Palach; M. Kusmider; M. Gaska; A. Faron-Gorecka; M. Dziedzicka-Wasylewska (S221-S222).

P.1.a.017 Effect of a functional NOS1 promoter polymorphism and life events on personality, anxiety and depressiveness by J. Harro; T. Kurrikoff; A. Reif; E. Kiive; S. Herterich; T. Tulviste; T. Veidebaum; K.P. Lesch (S222).

P.1.a.018 Alzheimer's disease risk and polymorphisms of the DHCR24 gene by A. Feher; A. Juhasz; A. Rimanoczy; J. Kalman; Z. Janka (S222-S223).

P.1.a.012 Association of aggressive traits with the 5-HTTLPR polymorphism in depressed and healthy women by X. Gonda; K.N. Fountoulakis; J. Lazary; D. Pap; M. Sasvari-Szekely; A. Veres-Szekely; G. Bagdy; G. Faludi; Z. Rihmer (S219).

P.1.a.007 Neurotrophin family genes (BDNF and NTRK2) and personality traits in healthy individuals by A. Kazantseva; A. Khannanova; T. Traks; S. Koks; E. Khusnutdinova (S216-S217).

P.1.a.010 The role of sigma-1 receptor polymorphism in the pathogenesis of Alzheimer's disease: preliminary results by A. Juhasz; A. Feher; A. Rimanoczy; M. Galfi; J. Kalman; Z. Janka (S218).

P.1.a.011 The study of prolactin gene polymophism in schizophrenic patients by J.K. Rybakowski; M. Dmitrzak-Weglarz; P. Kapelski; J. Hauser (S218-S219).

P.1.a.020 Expression of calcyon gene in rat brain after stressfull behavioural procedures by M. Kusmider; A. Faron-Gorecka; M. Gaska; P. Gruca; M. Papp; M. Dziedzicka-Wasylewska (S223-S224).

P.1.b.004 White matter microstructural alterations of the extrastriate visual cortex in women with anorexia nervosa by H. Frieling; T. Peschel; J. Fischer; T. Engelhorn; T. Hillemacher; S. Bleich; M. de Zwaan (S229).

P.1.b.007 Emotional face processing in the 5-HT2A model of altered states of consciousness using event-related potentials by A. Schmidt; P.A. Csomor; R. Bachmann; M. Kometer; F.X. Vollenweider (S231).

P.1.b.002 Motor tract white matter correlates with volitional motor behaviour in schizophrenia by S. Walther; H. Horn; A. Federspiel; N. Razavi; T. Dierks; W. Strik; T.J. Müller (S228).

P.1.b.001 Repetitive transcranial magnetic stimulation (rTMS) in the treatment of neuropatic pain by M. Klirova; J. Fricova; P. Sos; T. Novak; B. Tislerova; M. Haeckel; V. Masopust; R. Rokyta (S227-S228).

P.1.a.022 Preliminary study investigating the interferon gamma +874 T/A polymorphism and the somatic type of depression by T. Rimay; G. Daroczi; E. Kovacs; I. Benak; A. Feher; A. Juhasz; A. Vetro; M. Kovacs (S225).

P.1.a.021 Effects of desipramine treatment on hippocampal transcriptome in mice differing in responses to antidepressants by P. Lisowski; G.R. Juszczak; J. Goscik; L. Zwierzchowski; M. Wieczorek; A.H. Swiergiel (S224-S225).

P.1.a.005 A pilot study for family based association analysis of qualitative and quantitative traits for Korean schizophrenics by B. Lee; D. Kwon; Y. Kim; Y. Chung; J. Park; S. Kim; C. Kang; J. Kim; Y. Lee (S215-S216).

P.1.a.004 Associations between AVPR1b and NR3C1 gene variants and HPA axis responses to psychosocial stress by D. van West; J. Del-Favero; D. Deboutte; C. Van Broeckhoven; S. Claes (S214-S215).

S.27.04 Harmful psychiatric effects of plant cannabinoids in humans by C. Henquet; R. Kuepper; M. Konings; J. Van Os (S206).

S.27.02 Plant cannabinoids and psychiatric disorders: preclinical findings by D. Parolaro; D. Vigano; E. Zamberletti; C. Guidali; N. Realini; T. Rubino (S205).

S.26.02 Brain mechanisms in PTSD by E. Vermetten (S203).

S.26.03 PTSD and physical illness by C. Spitzer; B. Löwe; S. Barnow; H.J. Grabe (S204).

S.28.03 Abnormalities of glutamate and GABA systems in depression: novel findings from studies using MRS and PET by G. Hasler; A. Deschwanden; B. Karolewicz; F. Buck; S.M. Ametamey; W.C. Drevets; J.W. Van der Veen; J. Shen; V. Treyer (S207-S208).

S.28.04 The antidepressant potential of mGluR5 and GABA-B receptor antagonists in rodent models of depression by A. Pilc; A. Palucha-Poniewiera; J. Wieronska; K. Stachowicz; P. Branski; A. Siwek; M. Dybala; G. Nowak (S208).

E.05.02 Metabolic alterations and their background in patients with affective disorders by K. Kahl; S. Lampen-Inkamp; B. Claassen; T. Peschel; G. Schik (S211).

P.1.a.003 Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers by G. Bondolfi; E. Choong; M. Etter; B. Oneda; H. Tayebi; J.M. Aubry; C.B. Eap (S214).

E.02.01 Psychotropic drugs and pain mechanisms by J.A. Mico; E. Berrocoso (S209-S210).

P.1.c.031 Effect of almorexant treatment on sleep variables in patients with primary insomnia compared with healthy controls by G. Dorffner; P. Anderer; B. Saletu; G.M. Saletu-Zyhlarz; H. Danker-Hopfe; J. Black; J. Dingemanse; P. Hoever (S252-S253).

P.1.c.035 Role of 5-HT1A receptor on innate fear behavioural attentuation by cannabidiol in a prey versus predator paradigm by A. Uribe-Mariño; A. Francisco; M.A. Castiblanco-Urbina; A. Twardowschy; C.J. Salgado-Rohner; J.A.S. Crippa; J.E.C. Hallak; N.C. Coimbra (S255).

P.1.c.030 Second messengers in obsessive-compulsive disorder: role of adenylate-cyclase by D. Marazziti; S. Baroni; G. Consoli; M. Catena Dell'Osso; G. Giannaccini (S251-S252).

P.1.c.025 Longterm safety and efficacy outcomes in adults with ADHD treated with prolonged-release methylphenidate by B. Schaeuble; M. Hofecker; J. Buitelaar; S. Kooij; J. Dejonckheere; S. Waechter (S249).

P.1.c.026 Delayed effects of nociceptin analogue administration to anxiety and learning in juvenile rats by E.A. Ivanova; A.V. Malyshev; N.Y. Sarycheva; V.A. Dubynin; V.N. Kalikhevich; Z.A. Ardemasova; A.A. Kamensky (S249-S250).

P.1.c.027 Glucocorticoid receptors selectively modulate stress-evoked dopamine release in the prefrontal cortex by K. Butts; G. Vacca; S. Ahn; J. Weinberg; A.G. Phillips; A.H. Young (S250).

P.1.c.036 Nitric oxide modulation of memantine-induced deficits in sensorimotor gating in rats by C. Salum; N.F. Henriques-Santos; M.C. Brosco; E.A. DelBel (S255-S256).

P.1.c.047 Contribution of a1 subunit-containing GABA-A receptors to diazepam-induced motor impairment by J.M. Divljakovic; M. Van Linn; M.M. Milinkovic; W. Yin; B. Batinic; J.M. Cook; M.M. Savic (S261-S262).

P.1.c.048 Modulating effect of new L-valine derivatives on brain serotonin uptake in aggressive socially isolated mice by E. Encheva; S. Stancheva; L. Alova; L. Tancheva; V.V. Petkov; D. Tsekova (S262-S263).

P.1.c.049 Analysis of interaction between oxcarbazepine and COX-inhibitors in a rat model of inflammatory hyperalgesia by M. Tomic; S. Vuckovic; R. Stepanovic-Petrovic; A. Micov; N. Ugresic; M. Prostran; B. Boskovic (S263).

P.1.c.044 SH-I-048A, a novel positive modulator of GABA-A receptor: in vitro and behavioral profile by S.M. Joksimovic; S. Huang; J. Ramerstorfer; M.M. Milinkovic; J.M. Divljakovic; B.L. Roth; W. Sieghart; M.M. Savic; J.M. Cook (S260).

P.1.c.043 Midazolam impairs acquisition but not consolidation in water maze paradigm by M.M. Milinkovic; J. Samardzic; J.M. Divljakovic; S.M. Joksimovic; T. Timic; M.M. Savic (S259-S260).

P.1.c.039 Risperidone-induced hyperprolactinemia: reversal by aripiprazole by E. Esteban; G. Gomez; L. Pereyra; A. Mont (S257).

P.1.c.038 Psychopharmacological treatment of borderline personality disorder by R. Manzanero; I. Duran; M. Garcia; A. Chinchilla; A. Cebollada; M. Vega; A. Soto (S256-S257).

P.1.c.040 Impulsive aggression in a patient treated with levetiracetam by J.L. Villegas Martinez; J.A. Blanco Garrote; P. Marques Cabezas; G. Cabus Piñol; J. Coullaut García (S257-S258).

P.1.c.041 Interaction study between almorexant, a dual orexin receptor antagonist, and ethanol in healthy subjects by M. Hoch; J. Hay; P. Hoever; M. de Kam; J. van Gerven; J. Dingemanse (S258-S259).

P.1.c.023 Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach by K. Vucicevic; B. Miljkovic; M. Pokrajac; M. Prostran; Z. Martinovic; R. Velickovic; I. Grabnar (S247-S248).

P.1.c.004 Defensive effects of polyprenol-containing drug ropren in a model of subacute hepatosis with encephalopathy in rats by P.D. Shabanov; V.S. Sultanov; V.I. Roshchin; T.V. Nikitina; A.A. Lebedev; E.R. Bychkov; S.N. Proshin (S237).

P.1.c.006 Delayed effects of NR2B subunit-specific antagonist Ro 25–6981 on spatial memory in adult rats by O.A. Solovieva; A.T. Proshin; Z.I. Storozheva; V.V. Sherstnev (S238).

P.1.c.001 Acute psychomotor, memory and subjective effects of MDMA and THC (co-) administration over time in healthy volunteers by G. Dumont; J. van Hasselt; M. de Kam; J. van Gerven; D. Touw; J. Buitelaar; R. Verkes (S235-S236).

P.1.b.011 Thyroid hormones and exposure to violence in childhood in suicide attempters by C. Sinai; A.L. Nordstrom; P. Nordstrom; J. Jokinen (S233).

P.1.b.012 High prevalence of human herpesvirus 8 in a tunisian sample of schizophrenic patients by Y. El Kissi; N. Hannachi; S. Samoud; S. Gaabout; M. Ayachi; J. Boukadida; B. Ben Hadj Ali (S233-S234).

P.1.b.014 Deep brain stimulation of the nucleus accumbens for therapy-refractory obsessive-compulsive disorder by D. Denys; M. Mantione; M. Figee; P. van den Munckhof; F. Koerselman; H. Westenberg; R. Schuurman (S235).

P.1.c.008 Schizophrenia and neuroactive steroids in males by M. Bicikova; M. Hill; D. Ripova; P. Mohr; R. Hampl (S239-S240).

P.1.c.009 Role of the norepinephrine uptake transporter in the mechanism of action of MDMA (Ecstasy) by C.M. Hysek; M. Ineichen; V.G. Nicola; L. Simmler; M.E. Liechti (S240).

P.1.c.018 Increased serotonin 2c receptor editing in a mouse model of obesity by H. Schellekens; T.G. Dinan; J.F. Cryan (S245).

P.1.c.017 New pathway involved in the alteration of reflex bradycardia in response to stress: study in rats and mice by C. Sevoz-Couche; F. Netzer; J.F. Bernard; M. Hamon; J.J. Benoliel (S244-S245).

P.1.c.019 Effects of diazepam on contextual serial memory and hippocampal corticosterone in stressed middle-aged mice by C. Tronche; D. Beracochea; P. Liscia; M. Coutan; C. Pierard (S245-S246).

P.1.c.020 Effect of mycophenolate mofetil on behavioural and neuroimaging outcomes in transient focal cerebral ischemia in rats by A. Chauhan; K.H. Reeta; Y.K. Gupta; S.K. Mewar; U. Sharma; N.R. Jagannathan (S246).

P.1.c.016 Opposing roles of CB1 and TRPV1 in panic-like responses mediated by dorsal periaqueductal gray by A. Terzian; P. Casarotto; D.C. Aguiar; H. Zangrossi; F.S. Guimarães; C.T. Wotjak; F.A. Moreira (S244).

P.1.c.010 Lithium reduces neuropathic pain: involvement of opioid system by H.r. Banafshe; G. Hamidi; A. Mesdaghinia; M. Noorani Arani; M. Honarkar Ramezani (S240-S241).

S.25.05 Erythropoietin and neuroprotection by H. Ehrenreich (S202-S203).

S.25.04 Cannabinoids and neuroprotection by J. Ferníndez-Ruiz (S202).

S.07.08 Differential response to treatment across countries in a randomized clinical trial in mania by I. Pacchiarotti; E. Pappadopulos; F.S. Mandel; I. Lombardo; A. Loebel; E. Vieta (S174).

S.07.07 Addiction proneness: contribution of the endocannabinoid system and reward processing by H.H. van Hell; G. Jager; A. Brouwer; M.G. Bossong; R.S. Kahn; N.F. Ramsey (S174).

S.08.01 Involvement of hippocampal neurogenesis in the control of the HPA axis: evidence from animal models of affective disease by C. Belzung; A. Surget; A. Tanti; A. Laugeray; Q. Rainer; G. Griebel; R. Hen; C. Touma; P. Ruppert (S174-S175).

S.08.02 Chronic stress, depressive disorders and obesity: insights from animal models by A. Bartolomucci; V. Sanghez; C. Cero; V. Carola; C. Gross; A. Vidal-Puig; Z. Zukowska; S. Parmigiani; P. Palanza (S175).

S.07.06 Netrin G1 polymorphisms in cocaine and alcohol codependence vulnerability: from mice to men by S. Kelai; G. Maussion; N. Munoz; C. Boni; N. Ramoz; M. Simonneau; P. Gorwood (S173).

S.07.05 Abnormalities in reward prediction error signals in depression and schizophrenia by V. Gradin; P. Kumar; G. Waiter; T. Ahearn; I. Reid; C. Stickle; M. Milders; J. Hall; J.D. Steele (S173).

S.07.01 Role of Cdk5 activators in psychiatric diseases, learning and memory by O. Engmann; T. Hortobagyi; D. Bannerman; A.J. Thompson; K.P. Giese (S171).

S.07.02 Cued but not contextual fear conditioning impairment in the NMDA receptor subunit NR1-DbhCre transgenic mice by W. Solecki; K. Szklarczyk; J. Kubik; M. Sikora; J. Parkitna; R. Przewlocki (S171-S172).

S.07.04 CYP2D6 genotype predicts antidepressant dose in the GENDEP project by R. Keers; M. Ingelman-Sundberg; J. Hauser; W. Maier; M. Rietschel; O. Mors; P. McGuffin; A.E. Farmer; I.W. Craig; K.J. Aitchison (S172-S173).

S.08.05 New findings on the neurobiology of resilience and susceptibility to social stress by A.J. Eisch; D.C. Lagace; M.H. Donovan; N.A. DeCarolis; L.A. Farnbauch; S. Malhotra; O. Berton; E.J. Nestler; V. Krishnan (S176).

S.10.04 Ghrelin, leptin and other neurohormones involved in concerted regulation of brain and visceral functions by J. Epelbaum; M.C. Bourdel; R. Dardennes; B. Estour; B. Galusca; N. Germain; P.H. Gorwood; D. Grouselle; J.P. Olié; A. Pham-Scottez (S180).

S.10.03 Animal models of co-morbid depression and irritable bowel syndrome by J. Cryan; J.A. Bravo; G. Clarke; N.P. Hyland; D. O'Malley; D. O'Mahony; M. Julio-Pieper; D.P. McKernan; M. Tramullas; T.G. Dinan (S179-S180).

S.10.05 Brain imaging in patients with gastrointestinal disorders by E.A. Mayer; J. Labus; K. Tillisch (S180-S181).

S.12.01 Physiological and therapeutic relevance of constitutive activity at 5-HT2C receptors by U. Spampinato; A. Cathala; G.M. Leggio; M. Neny; F. Rouge-Pont; F. Drago; P.V. Piazza (S181).

S.12.03 Antidepressant-induced functional adaptive changes in 5-HT2C receptors: are they underlying their anxiolytic effects? by R. Mongeau; C.B.P. Martin; C. Chevarin; R. Maldonado; M. Hamon; P. Robledo; L. Lanfumey (S181).

S.09.03 Neurotrophic factors in autism by R. Riikonen; I. Makkonen; J. Kuikka; W. Kaufmann; U. Turpeinen; R. Vanhala; H. Kokki (S177-S178).

S.02.05 Genetics of tauopathies by J. Hardy (S163).

S.02.04 Physiopathological features of tauopathies and tau transgenic mice by L. Buée; S. Burnouf; L. Troquier; A. Leboucher; C. Laurent; H. Le Freche; J. Brouillette; M. Hamdane; N. Sergeant; D. Blum (S163).

S.03.03 Brain connectivity modulation by novel antipsychotics: an electrophysiological approach by M. Spedding; C. Sebban; T. Jay; E. Schenker; I. Gacsalyi (S164-S165).

S.02.03 Tau toxicity in cell and animal models by E.M. Mandelkow; E. Thies; A. Sydow; Y. Wang; J. Biernat; E. Mandelkow (S162-S163).

PL.03.01 Epigenetic regulation of cognitive functions by I. Mansuy; K. Koshibu; J. Graeff (S159).

S.01.04 Steroid-monoamine interactions in emotion by R. Hurlemann; O.A. Onur; J. Kukolja (S161-S162).

S.05.04 Glucocorticoids and noradrenaline in severe stress exposure in humans by G. Schelling; B. Roozendaal; P. Campolongo; D. de Quervain (S169-S170).

S.05.05 D-cycloserine and exposure therapy by B. Rothbaum; M. Davis; K. Ressler (S170).

S.04.07 Behavioural and neurochemical consequences of 5-HT transporter deletion on 5-HT2C receptor functions in mice by C.B.P. Martin; C. Chevarin; K.P. Lesch; M. Hamon; L. Lanfumey; R. Mongeau (S168).

S.04.01 Identification of a mouse febrile seizure susceptibility gene by E.V.S. Hessel; M. de Wit; I.G. Wolterink-Donselaar; H.A. van Lith; M.J.H. Kas; P.N.E. de Graan (S165-S166).

S.04.03 Inositol monophosphatase: drug target or false alarm? by N. Singh; S. Vasudevan; J. Thomas; O. Kuznetsova; M. Knight; P. Aley; T. Sharp; G. Churchill (S166).

S.04.04 Stress-induced alterations in hippocampal and amygdalar microRNAs: effects of lithium by R.M. O'Connor; O.F. O'Leary; A. Dinan; A. Gokul; T.G. Dinan; J.F. Cryan (S166-S167).

S.12.04 5-HT2C receptors and drug addiction by M. Filip; M. Zaniewska; A.C. McCreary (S182).

S.21.04 Arcuate NPY/AgRP neurons and the control of energy balance by S. Luquet; A. Joly; R. Denis; R. Palmiter; C. Magnan (S195-S196).

S.22.02 Alostatic load and oxidative stress in bipolar disorder by F. Kapczinski; K.M. Ceresér; M. Kauer-Sant'Anna (S196).

S.20.02 Alpha7 nicotinic receptors and synaptic plasticity by H.D. Mansvelder; R.B. Poorthuis; B. Bloem; K. Guillem (S193).

S.22.03 Neurocognition and psychosocial function in bipolar disorder by O.A. Andreassen; C. Simonsen; K. Sundet (S197).

S.22.04 Predictors of functioning in bipolar disorder by S. Dittmann; F. Seemüller; K. Hennig-Fast; R.R. Engel; M. Riedel; H.C. Grunze; W.E. Severus (S197).

S.24.05 Transgenic mouse models in addiction research by P. Robledo; E. Martín-García; A. Plaza-Zavala; F. Berrendero; R. Maldonado (S200-S201).

S.24.04 Endophenotypes of Disc1 missense mutations in mice by S.J. Clapcote; T.V. Lipina; J.C. Roder (S200).

S.25.02 Ion channels and exhangers as potential targets for stroke therapy by L. Annunziato; G. Pignataro; O. Cuomo; P. Molinaro; F. Boscia; A. Scorziello; A. Secondo; A. Pannaccione; R. Sirabella; G.F. Di Renzo (S201).

S.24.03 Genotype-phenotype relationships for psychiatric disorders; gender effects by A. Heinz; E. Friedel; F. Schlagenhauf; I. Puls (S200).

S.24.02 Cognitive endophenotypes in schizophrenia by M.F. Aukes; B.Z. Alizadeh; C. Kemner; M.M. Sitskoorn; R.A. Ophoff; R.S. Kahn (S199-S200).

S.23.01 Risk factors for Alzheimer's disease by H. Soininen; A. Solomon; M. Kivipelto (S198).

S.22.05 Neurobiological correlates of treatment response to psychoeducation by F. Colom; I. Pacchiarotti; A. Murru; A.M.A. Nivoli; E. Vieta (S197-S198).

S.23.02 Cholinergic imaging with PET by C. Haense; K. Herholz (S198).

S.24.01 Epigenetic effects on brain function and behaviour by L.S. Wilkinson; A.R. Isles; W. Davies; T. Humby (S199).

S.19.03 Neurobiology of fear-induced analgesia by D.P. Finn; M. Roche; G.K. Ford; K. Rea; W.M. Olango; R.K. Butler; B. Harhen; S.M. Geranton; S.P. Hunt (S192).

S.15.04 Systems biology approaches to study Parkinson's disease in C. elegans models by G. Wong; M. Lakso; S. Asikainen; S. Vartiainen; L. Heikkinen; R. Nass (S185).

S.16.01 Potential therapeutic targets from cellular/molecular signalling mechanisms in depression models by P. Svenningsson; T.M. Eriksson; K. Björk; S.O. Ögren; A. Mathe; M. El Yacoubi; J.M. Vaugeois (S186).

S.14.01 Shared and specific vulnerability in substance abuse by N. Ramoz; Y. Le Strat; P. Gorwood (S182-S183).

S.14.05 Place for baclofen in treating alcoholism by G. Colombo; P. Maccioni; M.A.M. Carai; G.L. Gessa (S184).

S.18.03 Genetics of obesity by J. Hebebrand; A. Hinney; A. Scherag (S190).

S.18.02 Genetics of anorexia nervosa by D.A. Collier; C.M. Bulik; P.F. Sullivan (S190).

S.18.05 Neurobiological mechanisms of hyperactivity in anorexia nervosa by R.A.H. Adan; L.A.W. Verhagen; S.L. Dickson; E. Egecioglu; R.J. DiLeone (S190-S191).

S.19.01 Cerebral correlates of pain and depression by K.J. Bär; J. Terhaar; G. Wagner; M.K. Boettger (S191).

S.19.02 Emotional behaviour and pain in animal models by C. Becker; C. Rivat; A. Blugeot; B. Zeau; J.J. Benoliel (S191).

P.1.c.050 SRA-444: an example of early drug development decision based on a positron emission tomography study by M. El Gaaloul; S. Raje; A. Lieuwe; W.d. Hirst; T. Andree; S. Chalon (S263-S264).

P.2.a.030 Deliberate self-harm and suicidal ideation in naturalistic outpatients: the Leiden routine outcome monitoring study by M.S. van Noorden; S. de Klerk; A.E. Giezen; P. Spinhoven; M.E. den Hollander-Gijsman; E.J. Giltay; A.E. Speckens; F.G. Zitman (S350-S351).

P.2.a.029 Pilot study on neurotrophin salivary levels in patients with major depression before and after escitalopram treatment by A. Iannitelli; E. Caroti; G. Bersani; I. Branchi; F. Cirulli; E. Alleva; L. Aloe; P. Tirassa (S350).

P.2.a.031 Prednisolone suppression test, but not dexamethasone predicts outcome in treatment resistant depression by M.F. Juruena; C.M. Pariante; A.S. Papadopoulos; L. Poon; S. Lightman; A.J. Cleare (S351-S352).

P.2.a.032 Amantadine: a treatment for major depressive disorder by A. Ruiz-Chow; J. Ramirez-Bermudez; L. Alviso-de la Serna; C. Rios (S352).

P.2.a.033 Therapy of anxiety-depressive disorders in outpatient cardiologic practice by N. Garganeyeva; A.I. Rozin; A.A. Evsyukov; D.S. Kaskayeva; A.V. Donov (S352-S353).

P.2.a.028 The effect of the number of depressive episodes on fatigue in female patients with major depression by P. Ferentinos; V.P. Kontaxakis; B.J. Havaki-Kontaxaki; D. Dikeos; G.N. Papadimitriou; L. Lykouras (S349-S350).

P.2.a.023 HPA axis hyperactivity is a vulnerability factor for switch to depressive disorder following interferon treatment by J. Eccles; C. Lallemant; F. Mushtaq; M. Greenwood; M. Keller; I. Haq; J. Tibble; R. Whale (S346-S347).

P.2.a.022 Current status of geriatric depression treatment in Korea by J. Paik; J. Kim; D. Moon; H. Ko (S346).

P.2.a.024 Quetiapine XR monotherapy and quetiapine XR+ongoing antidepressant versus lithium+ongoing AD for Stage II treatment-resistant major depressive disorder by M. Franco Martín; M.L. Figueira; P. Petrov; Z. Rihmer; L. Vavrusová; E. Dencker-Vansvik; L. Jörgensen; J. Köhler; M. Bauer (S347).

P.2.a.026 Superior efficacy results of agomelatine in a pooled analysis versus SSRI/SNRI by S. Kasper; A. Hale; P. Lemoine; M.A. Quera Salva (S348-S349).

P.2.a.034 Impact of methodology on the efficacy of extended release quetiapine fumarate in major depressive disorder by S. Montgomery; A. Kalali; R.S. McIntyre; W.R. Earley; S. Nyberg; H. Eriksson (S353).

P.2.b.012 Transcriptional changes of BDNF and clock genes in the rat prefrontal cortex following acute agomelatine administration by F. Calabrese; R. Molteni; G. Guidotti; C. Gabriel; E. Mocaer; G. Racagni; M.A. Riva (S360).

P.2.b.013 Mice with decreased vesicular glutamate transporter VGLUT1 levels show an altered presynaptic 5-HT function by A.L. García-García; N. Elizalde; E. Venzala; J. Del Rio; L. Lanfumey; R.M. Tordera (S360-S361).

P.2.b.008 Effect of different antidepressants on behavioural alterations induced by chronic social defeat stress by E. Venzala; A.L. García-García; N. Elizalde; P. Delagrange; R. Tordera (S357-S358).

P.2.b.007 Time defining effects of tryptophan depletion on hormone secretion and brain 5-HT2 binding in the rat by M. Franklin; I. Bermudez; S. Mucha; N. Singewald; S. Gaburro; H. Murck (S357).

P.2.b.004 Interconnectedness of homocysteine and affective disorders by S. Purvina; L. Kevere; D. Bauze; M. Zeibarts; A. Rizevs; S. Jelisejevs; M. Caune; I. Purvins; R. Andrezina (S355-S356).

P.2.b.006 Cognitive deficits and salivary cortisol in major depression: effects of treatment by K. Hinkelmann; S. Moritz; C. Muhtz; J. Botzenhard; K. Wiedemann; M. Kellner; C. Otte (S356-S357).

P.2.a.020 Treatment of breast cancer patients with comorbid serious anxiety and depression by Z. Snoj; M. Primic Zakelj; I. Vucko Miklavcic; M. Licina; P. Pregelj (S344-S345).

P.2.a.001 Cyclothymic and hyperthymic temperaments in depressive patients by S. Goto; T. Terao; Y. Araki; N. Hoaki; Y.M. Wang; Y. Takai (S333-S334).

P.2.a.003 Three polymorphisms of endothelial nitric oxide synthase (eNOS) gene and plasma NO3 levels by A. Ikenouchi-Sugita; R. Yoshimura; T. Kishi; W. Umene-Nakano; H. Hori; K. Hayashi; A. Katsuki; N. Iwata; J. Nakamura (S334-S335).

P.2.a.005 Unplanned versus planned suicide attempters: motives, methods, and mental disorders in a Korea-based community sample by H.J. Jeon; J.Y. Lee; Y.M. Lee; J.P. Hong; S.H. Won; S.J. Cho; J.Y. Kim; S.M. Chang; H.W. Lee; M.J. Cho (S336).

p.1.i.009 Behavioural and neurochemical characterisation of central neuropathic pain after spinal cord transection in the rat by S. MDahoma; R. Massart; F. Chali; D. Orsal; C. Chevarin; V. Kayser; S. Bourgoin; M. Hamon (S332-S333).

p.1.i.005 Long-term functional effects on circadian rhythm caused by a single MDMA treatment by Z. Kátai; T. Garay; B. Balogh; E. Kirilly; G. Bagdy (S330-S331).

P.1.i.007 Positive effects of an energy drink on driving performance during prolonged driving by M.A.J. Mets; S. Ketzer; C. Blom; M.H. Van Gerven; G.M. Van Willigenburg; B. Olivier; J.C. Verster (S331).

P.1.i.008 Functions and time scale of self-cutting in subjects suffering from borderline personality disorder by M. Muscionico; K. Dieben; R. Nicastro; N. Perroud; P. Huguelet (S332).

P.2.a.006 Predictors of remission in a national sample of patients with depressive disorders: the CRESCEND study by J.M. Kim; J.A. Yoo; S.J. Yang; S.W. Kim; I.S. Shin; J.S. Yoon; J.B. Kim; M.S. Lee; H.W. Lim; T.Y. Jun (S336-S337).

P.2.a.007 Comorbid physical disorders and 12 week treatment outcomes in Korean patients with depressive disorders by J.A. Yoo; J.A. Kim; S.J. Yang; S.W. Kim; I.S. Shin; J.S. Yoon; J.B. Kim; M.S. Lee; H.W. Lim; T.Y. Jun (S337).

P.2.a.016 Cytokine profile in treatment-resistant depression by L.A. Carvalho; J.P. Torre; A.J. Cleare; C.M. Pariante (S342-S343).

P.2.a.015 Transcranial direct current stimulation in patients with treatment-resistant major depressive episode by B. Dell'Osso; S. Zanoni; F. Castellano; C. Dobrea; B. Benatti; C. Arici; R. Ferrucci; M. Vergari; A. Priori; A.C. Altamura (S341-S342).

P.2.a.017 Acute deep brain stimulation in the subgenual cingulate alters REM sleep in patients with treatment resistant depression by C. Durant; A.L. Malizia; L. Paterson; A. Rich; D.J. Nutt; S. Gill; N.K. Patel; S. Wilson (S343).

P.2.a.018 Influences between defense mechanisms and antidepressants on the therapeutic compliance in major depressive disorder by D. Vasile; O. Vasiliu; M.L. Vasile; M. Terpan; A. Mangalagiu; V. Bogdan; D. Ojog; M.B. Petrescu; I. Paraico (S343-S344).

P.2.a.019 Memory and executive functions in patients treated with vagus nerve stimulation for refractory depression by V. Desbeaumes; F. Richer; E. LaGarde; S. Patry; A. Bouthillier; P. Lespérance (S344).

P.2.a.014 5-HTTLPR SS depressed women: higher baseline thyroid-stimulating hormone and lower antidepressant response by F. Gressier; S. Trabado; C. Verstuyft; P. Hardy; B. Fève; L. Becquemont; E. Corruble (S341).

P.2.a.009 Nonadherence to paroxetine; comparison between early-remitters and late-remitters by J. Nakamura; R. Yoshimura; A. Ikenouchi-Sugita; H. Hori; W. Umene-Nakano; A. Katsuki; N. Ueda (S338).

P.2.a.010 The cortisol awakening response in patients remitted from depression by J.M. Aubry; F. Jermann; M. Gex-Fabry; L. Bockhorn; M. Van der Linden; N. Gervasoni; G. Bertschy; F.M. Rossier; G. Bondolfi (S339).

P.2.a.012 Do we treat different patients with different antidepressant? Clinical and economic assessments in Spanish setting by M. Blanca-Tamayo; A. Sicras-Mainar; B. Pascual-Arce; L. García-Sánchez; M.C. Pérez-Navarro; R. Navarro-Artieda; N. Muro-Perea (S340).

P.2.b.014 Desipramine reduces lipopolysaccharide-induced interleukin-1beta in brain and plasma of rats by E. Obuchowicz; A. Prymus; A.M. Bielecka; L. Drzyzga; M. Paul-Samojedny (S361).

P.2.b.015 Mediating role of psychological immune competencies on the development of susceptibility to depression by D. Pap; X. Gonda; J. Lazary; E. Molnar; L. Tothfalusi; G. Bagdy (S361-S362).

P.2.c.028 Effect of a single dose (50 mg) of agomelatine on bold fMRI responses to face emotion recognition in healthy volunteers by J. Lees; S. McKie; R. Dadhiwala; P. Horgan; G. Dawson; L. Seguin; E. Mocaër; J.F.W. Deakin (S383-S384).

P.2.c.029 Risk factors of drug interaction between warfarin and antidepressant in a clinical setting by R. Na; J.P. Hong; K.W. Kim; J.W. Choi; S.J. Park; K.K. Yi (S384).

P.2.c.030 Serum brain-derived neurotrophic factor levels as predictor of antidepressant therapy response by A. Eckert; M. Giese; J. Beck; S. Brand; F. Muheim; M. Hatzinger; E. Holsboer-Trachsler (S384-S385).

P.2.c.024 Switching to second line antidepressant in the United Kingdom: main characteristics and determinants by J. Chollet; D. Saragoussi; N. Despiegel; K. Maman; D. Milea (S381-S382).

P.2.c.020 Effects of mirtazapine on brain-derived neurotrophic factor (BDNF) and catecholamine metabolites by A. Katsuki; R. Yoshimura; A. Sugita; H. Hori; W. Nakano; K. Hayashi; J. Nakamura (S379).

P.2.c.019 Polypharmacy in psychiatry: clinical practice versus empirical evidence by K. Lötscher; I.G. Anghelescu; S. Braun; R. Bridler; H.H. Stassen (S378-S379).

P.2.c.021 Agomelatine facilitates positive emotional processing in healthy volunteers by G.M. Goodwin; C. de Bodinat; G.R. Dawson; C.T. Dourish; L. Waldenmaier; S. Adams; P.J. Cowen; C.J. Harmer (S379-S380).

P.2.c.032 Adjunctive aripiprazole in major depressive disorder (MDD): efficacy and predictors of remission by J.C. Nelson; M.E. Thase; R.A. Baker; L.M. Rollin; R.D. McQuade; R.N. Marcus; R.M. Berman; S.R. Wisniewski; R. Gismondi; J.Y. Loze (S386).

P.2.d.002 Antidepressant activity of Iranian Corn Silk by M. Mahmoudi; S. Ehteshami (S392).

P.2.d.001 Antidepressant properties of ketamine plus imipramine treatment: behavioural and molecular studies in rats by G.Z. Réus; R.B. Stringari; K.F. Ribeiro; A.K. Ferraro; M.J.S. Frederico; M.F. Vitto; P. Cesconetto; C.T. Souza; J. Quevedo (S391).

P.2.d.006 Role of PSA-NCAM in the structural plasticity associated to dopaminergic antidepressants in the medial prefrontal cortex by E. Castillo-Gómez; M.A. Gómez-Climent; C. García-Mompó; J. Nácher (S393-S394).

P.2.c.039 Noradrenergic uptake inhibition of higher doses of paroxetine in relation to clinical efficacy: the DELPHI-study by H.G. Ruhe; R. van Westrhenen; M.W. Koeter; M.C. Michel; H.H. Sitte; A.H. Schene (S390-S391).

P.2.c.034 Duloxetine versus sertraline in the treatment of post-stroke depression by E. Tzavellas; D. Karaiskos; K. Spengos; E. Economou; G.N. Papadimitriou; I. Liappas; T. Paparrigopoulos (S387).

P.2.c.033 Influence and interaction of genetic polymorphisms in serotonin system and early life stress on antidepressant response by Z.J. Zhang; Z. Xu; Y.Y. Shi; M.J. Pu; C.Y. Wang; Z.N. Liu; G.P. Reynolds (S386-S387).

P.2.c.035 Effect of phospholipase C enzyme gene and environmental factors on antidepressant treatment in Han Chinese population by Z.J. Zhang; Y.Y. Shi; Z. Xu; M.J. Pu; C.Y. Wang; Z.N. Liu; G.P. Reynolds (S388).

P.2.c.037 The serotonin transporter (SERT) occupancy in median raphe nucleus quantified with PET predicts treatment response to SSRIs in major depressive disorder by E. Akimova; R. Lanzenberger; M. Savli; D. Häusler; W. Wadsak; C. Spindelegger; U. Moser; M. Fink; K. Kletter; S. Kasper (S389).

P.2.c.018 Safety of quetiapine for treatment of insomnia in patients with major depressive disorder by S. Lee; J.H. Han; S.C. Hong; J.H. Jeong; H.J. Seo; H.K. Lim (S377-S378).

P.2.b.023 Rodent magnesium-deficiency models for depression and their relationship to NMDA receptor/Nitric Oxide pathways by N. Singewald; S.B. Sartori; S. Gaburro; C. Schmuckermair; A. Hetzenauer; A. Rjabokon; M. Franklin; I. Bermudez; H. Murck; J.H. Shin; L. Lin; G. Lubec; N. Whittle (S366).

P.2.b.025 Serotonin uptake in blood platelets is related to cingulate cortex activation by C. Kasess; C. Scharinger; G. Pail; Z. Uzelac; M. Freissmuth; S. Kasper; E. Moser; H. Sitte; L. Pezawas (S367).

P.2.c.001 Adding an atypical antipsychotic drug induced a rapid increase of plasma BDNF levels in refractory depression by R. Yoshimura; A. Ikenouchi-Sugita; H. Hori; W. Umene-Nakano; A. Katsuki; K. Hayashi; J. Nakamura (S367-S368).

P.2.b.022 Serum BDNF levels correlate with arousal status in women by G. Bersani; A. Iannitelli; P. TIrassa; F. Cirulli; I. Branchi; L. Aloe; E. Alleva (S365-S366).

P.2.b.021 Escitalopram in the treatment of depression by I. Duran; R. Gomez; P. Sanchez; T. Alvarez; A. Chinchilla; M. Vega; A. Cebollada; R. Manzanero; A. Regidor; M. Serrano (S365).

P.2.b.017 Defining endophenoypes in major depressive disorder: anhedonia, neuroticism and psychomotor speed by E. Vrieze; K. Demyttenaere; R. Bruffaert; M. Schmidt; P. de Boer; S. Claes (S362-S363).

P.2.b.018 Mouse communal nest: early social enrichment blunts adult depression-like phenotype altering BDNF epigenetic structure by I. Branchi; I. D'Andrea; S. Santarelli; F. Cirulli; N. Karpova; E. Castrén; E. Alleva (S363-S364).

P.2.b.019 Agomelatine has antidepressant effects and modifies BDNF and neuronal plasticity markers in the rat PFC and hippocampus by M. Bianchi; C. Potard; N. Ladurelle; C. Gabriel; E. Mocaer; E.E. Baulieu (S364).

P.2.c.013 New functional variant in SLC6A4 gene as candidate of the individualised treatment of depression – the result of an RCT - by M. Kato; S. Tetsuo; M. Wakeno; S. Nonen; G. Okugawa; Y. Takekita; J. Azuma; T. Kinoshita (S374-S375).

P.2.c.014 Agomelatine: a new therapeutic prospective in depression by C. Istikoglou; D. Foutsitzis; A. Vlavianou; P. Kanellos; N. Polonifis; D. Vlissides; K. Michelidakis; G. Theodorakopoulos (S375-S376).

P.2.c.015 Do our patients comply with antidepressant treatments? by J.I. Castro; S. Oller; M.I. Fernández; L.M. Martín; D. Flamarich; D. Lacasta; R. García; M.T. Font (S376).

P.2.c.016 Sertraline versus mirtazapine in treatment of depression in Parkinson's disease by G. Djokic; D. Pavicevic; N. Zivkovic; M. Nenadovic; N. Nenadovic; D. Duisin (S376-S377).

P.2.c.011 The effect of carbamazepine co-therapy on the extent of MAO-A inhibition by moclobemide in depressed patients by A. Rakic Ignjatovic; B. Miljkovic; D. Todorovic; I. Timotijevic; M. Pokrajac (S373-S374).

P.2.c.005 Plasma homovanillic acid levels and 5-HTTLPR gene polymorphism are predictive factors for sertraline in Japanese depressed patients by W. Nakano; R. Yoshimura; N. Ueda; A. Suzuki; A. Ikenouchi-Sugita; H. Hori; K. Otani; J. Nakamura (S370).

P.2.c.007 Efficacy of mirtazapine in depressed outpatients with an enduring personality change after a catastrophic experience by M. Stojakovic; S. Medenica; B. Stojakovic; D. Trkulja; S. Vukadinovic; N. Selman; S. Ristic (S371).

P.2.c.008 Assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease by M. Mancini; G. Meco; G. Tedeschi; G. Fabbrini; P. Stanzione; F. Stocchi; R. Ceravolo; M. Guadagna; G. Dell'Agnello; U. Bonuccelli (S372).

P.1.i.002 Changes in cerebrospinal fluid insulin during non-neurological surgery by S. Bromander; R. Anckarsäter; B. Ahrén; M. Kristiansson; K. Blennow; H. Zetterberg; H. Anckarsäter; C. Wass (S328-S329).

P.1.d.021 Evaluation of the novel anxiolytic compound BNC210 in a rodent model of cholecystokinin-induced panic by S. O'Connor; B. Huyard; G. Kremmidiotis; S. Wagner; E. Andriambeloson (S285).

P.1.d.020 Role of interferon-gamma on anxiety-like behaviour in mice by V.M. Saito; D.H. Rodrigues; A.L. Teixeira; F.A. Moreira (S284-S285).

P.1.d.022 GABAergic synaptic coverage of principal cells in the hippocampus in the rat model of schizophrenia by N. Radonjic; I. Jakovcevski; V. Bumbasirevic; N. Petronijevic (S285-S286).

P.1.d.023 Effect of sex hormones on pain-related behaviour in rats by E. Shekunova; A. Malyshkin; I. Belozertseva (S286).

P.1.d.019 Circadian pattern of wheel running activity of four laboratory mouse strains by M. Ágoston; J. Wellmann; P. Delagrange; M. Spedding; I. Gacsályi; G. Szénási (S284).

P.1.d.018 Memory consolidation via membrane glucocorticoid receptors that can be blocked by cannabinoid receptor antagonists by D. Hauer; R.V. Fornari; P. Atsak; P. Campolongo; G. Schelling; B. Roozendaal (S283-S284).

P.1.d.014 HFS and pharmacological inactivation of the globus pallidus and nucleus entopeduncularis differentially affect quinpirole-induced compulsive checking in rats by A. Djodari-Irani; J. Klein; J. Banzhaf; G. Juckel; A. Heinz; A. Kupsch; R. Morgenstern; C. Winter (S281-S282).

P.1.d.016 Acute effects of modafinil on affective behaviour in aggressive and timid male mice by A. Máchalová; D. Vrsková; K. Slais; A. Sulcová (S282-S283).

P.1.d.017 Dissociation between anhedonia, anxiety and brain BDNF levels in a mouse model of social stress by A. Berry; V. Bellisario; S. Capoccia; E. Alleva; P. Tirassa; F. Cirulli (S283).

P.1.e.011 Fronto-limbic interaction of working memory and emotion in the medial prefrontal cortex by G. Pail; W. Huf; C. Kasess; S. Kasper; E. Moser; B. Brocke; A. Meyer-Lindenberg; V.S. Mattay; D.R. Weinberger; L. Pezawas (S294).

P.1.e.012 Is there a link between amygdala volume, cognitive function and childhood trauma in first-episode psychosis? by M. Aas; P. Dazzan; A. Gibbs; C. Morgan; H.L. Fisher; A. Reichenberg; J. Zanelli; K. Morgan; R. Murray; C.M. Pariante (S294-S295).

P.1.e.013 Irony comprehension in bipolar disorder: an fMRI study by M. Simon; E. Varga; A.S. Hajnal; G. Orsi; T. Tenyi; S. Fekete; R. Herold (S295).

P.1.e.008 Impact of genetic polymorphism on resting state functional connectivity in healthy subjects by M.S. Byun; W.H. Jung; J.H. Jang; D.H. Kang; S.J. Kwon; C.H. Choi; J.S. Kwon (S292-S293).

P.1.e.007 Abnormal cortical neurotransmitter levels in young people at familial risk of depression by M.J. Taylor; Z.N. Mannie; R. Norbury; J. Near; P.J. Cowen (S292).

P.1.e.003 White matter microstructure in transsexuals by E. Gómez-Gil; G. Rametti; B. Carrillo; C. Junque; S. Segovia; A. Gómez; A. Guillamon (S289).

P.1.e.002 Diffusion tensor imaging findings in early-onset schizophrenia patients by M. Gawlowska; P. Gebski; J. Rabe-Jablonska (S288-S289).

P.1.e.004 Effects of minocycline on regional cerebral blood flow in schizophrenia by C. Marque; C. Chaves; L. Wichert-Ana; J.A.S. Crippa; A.W. Zuardi; G.B. Baker; F.S. Guimarães; S.M. Dursun; J.E.C. Hallak (S290).

P.1.e.005 Delta9-tetrahydrocannabinol (THC) impairs working memory system capacity: a pharmacological MRI study by M.G. Bossong; H.H. van Hell; G. Jager; F.A. Oudman; R.S. Kahn; N.F. Ramsey (S290-S291).

P.1.e.006 Differential brain changes in males with early-onset psychotic disorders by diagnosis by C. Moreno Ruiz; M. Rapado-Castro; S. Reig; J. Castro-Fornieles; A. González-Pinto; J. Janssen; M. Parellada; I. Baeza; M. Desco; C. Arango (S291).

P.1.d.012 Individual differences in the expression of prepulse inhibition predict the magnitude of amphetamine sensitisation by D. Peleg-Raibstein; J. Hauser; L.L. Lopez; P.A. Gargiulo; J. Feldon; B.K. Yee (S280).

P.1.d.011 Effects of excitotoxic lesions of the CA1 region of the hippocampus on acquisition of a place and cue water maze task by N. Chkhikvishvili; M. Burjanadze; G. Maglakelidze; R. Sakandelidze (S279-S280).

P.1.c.062 Effects of glutamic acid on signaling and structural proteins of rat brain endothelial cells in ischaemic conditions by A. Malecki; J. Bernacki; K. Nierwinska; A. Pudelko; A. Dobrowolska (S270-S271).

P.1.c.053 The effect of olanzapine on a tetrahydrocannabinol-induced increase on the positive and negative syndrome scale by H.D. Kleinloog; M. Liem-Moolenaar; G.E. Jacobs; M.L. de Kam; J.M.A. van Gerven (S265).

P.1.c.064 Decreased neuregulin-1 in the cortex of rat pups as immediate effect of perinatal phencyclidine treatment by N. Petronijevic; T. Nikolic; N. Radonjic; U. Vilimanovich; V. Trajkovic; V. Bumbairevic (S271-S272).

P.1.c.065 Neuroprotection signalling after electroconvulsive stimulation by D. Rosa; R. Souza; A. Barros; F. Lima; G. Feier; J. Quevedo; M. Romano-Silva (S272).

P.1.d.008 Diacylglycerol kinase β knockout mice show an abnormal response on psychostimulant-induced behavioural change by H. Hara; K. Kakefuda; M. Ishisaka; A. Oyagi; K. Tsuruma; M. Shimazawa; K. Yokota; N. Saito; K. Fukunaga; J. Takeda (S278).

P.1.d.009 Longterm memory formation in non-association learning task in sham-operated and dentate gyrus lesioned rats by T. Naneishvili; M. Dashniani; G. Beselia; A. Noselidze; L. Kruashvili (S278-S279).

P.1.d.001 Marinobufagenin, an endogenous Na pump inhibitor, is implicated in social behavior of mice by V.A. Kashkin; I.V. Belozertseva; E.V. Shekunova; E.E. Zvartau; A.Y. Bagrov (S274).

P.1.d.003 Advantageous effect of deramciclane in the NaN3 model of Alzheimer's disease in rats by K. Megyeri; K. Móricz; I. Nagyné-Gyönös; M. Albert; I. Gacsályi (S275).

P.1.e.015 Emotion cognition interaction located using surface-based versus volume-based analysis by W. Huf; G. Pail; B. Hartinger; C. Kasess; S. Kasper; V.S. Mattay; A. Meyer-Lindenberg; E. Moser; D.R. Weinberger; L. Pezawas (S296-S297).

P.1.g.017 American ginseng improves human neurocognitive function: a randomized, double-blind, placebo-controlled, crossover study by A. Scholey; A. Ossoukhova; L. Owen; A. Pipingas; M. Kras; A. Ibarra; C. Stough (S318).

P.1.g.018 Genetic, neurophysiologic and behavioural factors in human risk taking behaviour: an endophenotype by I. Heitland; R.S. Oosting; J.M.P. Baas; J.L. Kenemans; K.B.E. Böcker (S318-S319).

P.1.g.019 The effect of acute cold stress on long term potentiation in rats by A.S. Artis; N. Dolu; L. Sahin; A. Cetin; C. Suer (S319).

P.1.g.020 Computerised cognitive testing in schizophrenia: patients' experiences by S. Pandey-Bhat; G. Nath; A. Arneja; A. Sharma; H. Kaviani; S. De Santi (S319-S320).

P.1.g.014 Cognitive and neurophysiological performance following scopolamine and ketamine administration in a crossover study by N. Levy-Cooperman; D. Milovan; A. Reches; N. Pinchuk; M.K. Romach; G. Ben Bashat; R. Shani-Hershkovitch; L.Y. Deouell; A.B. Geva; E.M. Sellers (S316).

P.1.g.011 Assessing cognitive impairment to define needs for care in a sample of chronic outpatients with schizophrenia by G. Cerveri; V. Venturi; L.S. Volonteri; A. Mazzocchi; C. Mencacci (S314-S315).

P.1.g.022 Decision-making in euthymis bipolar disorders: their relationship with suicidal behaviour by D.J. Martino; S.A. Strejilevich; T. Torralva; F. Manes (S320-S321).

P.1.h.006 Detection of substances of abuse in emergency department: is there an increasing the use of benzodiazepines? by M. Mola Gibert; R. Pou Calvo; L. Montesinos Rueda; E. Gine Serven; A. Alvarez Gomez; E. Batlle de Santiago (S325-S326).

P.1.h.008 Aggression on a psychiatric acute ward: predictors and clinical assessments by M. Stinga; C. Papastergios; K. Papanikolaou; E. Papageorgiou; M. Ntavou; N. Voura; G.F. Angelidis (S326-S327).

P.1.h.005 Sleep quality and depression among nursing home residents by F.O. Orhan; D. Tuncel; F. Tas; N. Demirci; A. Özer; M.F. Karaaslan (S325).

P.1.g.023 No evidence of differences in neurocognitive functioning among euthymic bipolar I and bipolar II disorders by D.J. Martino; A. Igoa; E. Marengo; G. Fassi; S.A. Strejilevich (S321-S322).

P.1.h.001 Comparison of treated and untreated major depressive disorder in a nationwide sample of Korean adults by K. Kim; S. Park; J.W. Choi; J.I. Park; J.P. Hong; M.J. Cho (S322-S323).

P.1.h.002 A different psychiatric diagnosis with similar economic impact in primary care setting: comorbidity and associated cost by M. Blanca-Tamayo; A. Sicras-Mainar; B. Pacual-Arce; N. Muro-Perea; R. Navarro-Artieda; L. García-Sánchez; M.C. Pérez-Navarro (S323).

P.1.h.003 Prevalence of metabolic syndrome and cardiovascular risk in patients with schizoaffective disorders by A. Benabarre; M.P. García-Portilla; L. Livianos; F. Mesa (S323-S324).

P.1.e.025 Dysfunctional reward circuitry in obsessive-compulsive disorder by M. Figee; M. Vink; F. de Geus; N.C.C. Vulink; D.J. Veltman; H.G.M. Westenberg; D.A.J.P. Denys (S302).

P.1.e.024 Effect of antidepressant treatment on the neural circuitry in dysthymia: a functional magnetic resonance imaging study by A. Ravindran; A. Smith; T. Georgescu; C. Cameron; R. Bhatla; M. Hogan (S301-S302).

P.1.e.026 [11C]AF150(S): a putative agonist PET ligand for in vivo imaging of the M1 muscarinic acetylcholine receptor by J.E. Leysen; J.C. Buiter; A. Fisher; M.C. Huisman; M. Yaqub; R. Boellaard; A.A. Lammertsma; A.D. Windhorst (S302-S303).

P.1.e.027 Voxel-based morphometry in affected and unaffected offspring of bipolar parents by T. Novak; M. Kopecek; J. Horacek; T. Hajek; C. Hoschl (S303).

P.1.e.028 Increase of whole brain volume and gray and white matter tissue in OCD: a volumetric and voxel-based morphometry MRI study by T. Sobanski; G. Wagner; G. Peikert; U. Gruhn; H. Sauer; R.G. Schlösser (S303-S304).

P.1.e.023 Dopaminergic activity in Tourette's syndrome and obsessive-compulsive disorder by F.E. de Vries; D. Denys; D.C. Cath; M. Figee; D.J. Veltman; T.F. van der Doef; R. Boellaard; A.J.L.M. Balkom; A.A. Lammertsma; B.N.M. van Berckel (S300-S301).

P.1.e.022 Cathechol-O-methyltransferase genotype biases neural correlates of empathy and perceived personal distress in schizophrenia by S. Poletti; D. Radaelli; R. Riccaboni; R. Cavallaro; S. Smeraldi; F. Benedetti (S300).

P.1.e.016 Cortisol awakening response and cerebral serotonin transporter binding by V.G. Frokjaer; D. Erritzoe; P. Jensen; J. Madsen; W. Baaré; G.M. Knudsen (S297).

P.1.e.018 Focal and global brain measurements in non-psychotic siblings of patients with schizophrenia by H. Boos; W. Cahn; N.E.M. Van Haren; E.M. Derks; R.M. Brouwer; H.G. Schnack; H.E. Hulshoff Pol; R.S. Kahn (S298-S299).

P.1.e.030 Clinical response of neuronavigated repetitive-TMS in the treatment of auditory hallucinations by M. Klirova; J. Horacek; T. Novak; J. Cermak; B. Tislerova; J. Tintera (S304-S305).

P.1.g.003 Cognitive and perceptual processing in body dysmorphic disorder by K. Jefferies; K. Laws; G. Hranov; N.A. Fineberg (S309-S310).

P.1.g.001 A prospective investigation of postconcussional symptoms after mild traumatic brain injury by R. Hou; R. Peveler; R. Moss-Morris; A. Belli; S. McVeigh; B. Bradley; K. Mogg (S308-S309).

P.1.f.005 Risk of development of premenstrual symptoms is associated with a traitlike negative bias in perception of life events by X. Gonda; K.N. Fountoulakis; G. Csukly; T. Telek; D. Pap; Z. Rihmer; G. Bagdy (S308).

P.1.f.001 Temperament and character profiles in female fibromyalgia syndrome patients and healthy controls by Ö. Altunören; F.O. Orhan; V. Nacitarhan; A. Özer; M.F. Karaaslan; O. Altunören (S305-S306).

P.1.f.002 Personality and help-seeking attitudes of people with mental health problems by K. Krysta; J. Brzezicki; S. Lech; M. Janas-Kozik; A. Klasik (S306).

P.1.f.003 Psychopathology assessment of fifty patients with morbid obesity who applied for bariatric surgery by E. Perez Martinez; C.J. van der Hofstadt; S. Tirado Gonzalez; M. Mateu Vicente (S306-S307).